Clinical trial register · Spain

Clinical Trials in Barcelona, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746

Trials with a site in Barcelona

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Recruiting

Personalised Monitoring of Early and Intermediate Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression

NCT06351670Age-Related Macular Degeneration

Medical University of Vienna

Observational

500

Barcelona

2025-02-25

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

NCT06646276Extensive-Stage Small Cell Lung Cancer

DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin

Bristol-Myers Squibb

Phase 3

530

Santiago de Compostela, Barcelona, Jaén, Madrid, Majadahonda, Valencia, Seville

2025-02-25

Active, closed

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

NCT06617793Relapsing Multiple Sclerosis

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 1/2

Barcelona, Córdoba, Madrid, Valencia

2025-02-24

Active, closed

Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI

NCT06811805AKI - Acute Kidney Injury, Cardiac Surgery Associated - Acute Kidney Injury

CardioRenal Systems, Inc.

Not applicable

300

Barcelona, Madrid

2025-02-23

Active, closed

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

NCT06878404Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

552

A Coruña, Barcelona, Córdoba, Madrid, Málaga, Sabadell, Santander, Seville

2025-02-21

Recruiting

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

NCT06567782Neoplasms, Colon

DrugsCapeox·Dostarlimab

GlaxoSmithKline

Phase 2

120

Barcelona, Madrid, Oviedo, Valencia

2025-02-18

Recruiting

A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections

NCT06828848Gram Negative Infections

DrugMeropenem

Menarini Group

Phase 2

Barcelona, Cadiz, Girona, Madrid, Málaga, Santiago de Compostela

2025-02-18

Recruiting

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions

NCT07091682Coronary Artery Disease, Atherosclerosis of Coronary Artery, Myocardial Ischemia, Ischemic Heart Disease

Biotronik AG

Not applicable

100

Barcelona, Madrid, Valladolid

2025-02-18

Recruiting

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

NCT06697197Advanced Solid Tumors

DrugsNivolumab and rHuPH20·Opdualag·Bevacizumab

Bristol-Myers Squibb

Phase 1/2

413

Barcelona, Pamplona, Madrid

2025-02-17

By invitation

Development of an International Remote Digital Care System for Accessible, Inclusive and Sustainable Pregnancy Care

NCT07191236Telemedicine, Digital Health, Pregnancy Complications

UMC Utrecht

Observational

450

Barcelona

2025-02-17

Recruiting

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

NCT06612268Sickle Cell Disease

DrugEtavopivat

Novo Nordisk A/S

Phase 3

510

Barcelona, Madrid, Seville

2025-02-17

Active, closed

Observational Study to Evaluate Fertility in Women Between 32 and 38 Years Old Treated With the Ovosicare® Fertility

NCT07083999Fertility

Procare Health Iberia S.L.

Observational

300

Sitges, Getafe, Benalmádena, Estella-Lizarra, A Coruña, Alicante, Almería, Barcelona

2025-02-13

Recruiting

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06760819Advanced Solid Tumors, HER2 Mutation

DrugSevabertinib

Bayer

Phase 2

111

L'Hospitalet de Llobregat, Barcelona, Madrid

2025-02-13

By invitation

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

NCT06908226Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

324

Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga, Valencia

2025-02-12

Active, closed

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834347Chronic Rhinosinusitis With Nasal Polyps

DrugsItepekimab·Mometasone furoate

Sanofi

Phase 3

231

Santiago de Compostela, Barcelona, Jerez de la Frontera, Majadahonda, Seville, Sabadell, Zaragoza

2025-02-12

Recruiting

Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels

NCT06334575Chronic Obstructive Pulmonary Disease

DrugBudesonide

Maria Joyera Rodríguez

Phase 4

135

Barcelona, Palma de Mallorca

2025-02-12

Recruiting

The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

NCT05973786Bipolar Depression

DrugsValproate acid·Lithium·Bupropion·Venlafaxine

Dr. Inge Winter

Phase 3

418

Barcelona

2025-02-11

Recruiting

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

NCT06858579Chronic Inflammatory Demyelinating Polyneuropathy

DrugClaseprubart

Dianthus Therapeutics

Phase 3

256

Barcelona, Alicante, Bilbao

2025-02-10

Active, closed

Impact of a Tele-rehabilitation Program on People With Multiple Sclerosis

NCT07178834Multiple Sclerosis

Multiple Sclerosis Center of Catalonia

Not applicable

Barcelona

2025-02-10

Active, closed

Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

NCT06806293Menstrual Migraine (MM)

DrugAtogepant

AbbVie

Phase 3

468

Barcelona, Madrid, Valladolid

2025-02-10

Not yet open

BALNEOTHERAPY FOR BREAST CANCER PATIENTS UNDERGOING ENDOCRINE THERAPY

NCT06806072Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Parc de Salut Mar

Not applicable

Barcelona

2025-02-10

Active, closed

A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

NCT06748053Asthma

DrugGSK5784283

GlaxoSmithKline

Phase 2

307

Alcorcon Madrid, Barcelona, Benalmádena, Jerez de la Frontera, Madrid, Málaga, Santander, Seville

2025-02-10

Active, closed

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

NCT06744920Generalized Myasthenia Gravis

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

180

Barcelona, Lleida, Madrid, Málaga, Valencia

2025-02-07

Active, closed

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834360Chronic Rhinosinusitis With Nasal Polyps

DrugsItepekimab·Mometasone furoate

Sanofi

Phase 3

216

Barcelona, Santander, L'Hospitalet de Llobregat, Pamplona, Madrid

2025-02-06

Active, closed

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

NCT06843239Systemic Sclerosis (SSc), Scleroderma

Zura Bio Inc

Phase 2

Barcelona, Seville

2025-02-06

Recruiting

RELIEF: Multimodal Prehabilitation to Treat Fatigue in Patients With Primary Biliary Cholangitis

NCT07161245Primary Biliary Cholangitis (PBC)

Hospital Clinic of Barcelona

Not applicable

Barcelona

2025-02-06

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

NCT06624670Pyoderma Gangrenosum

DrugsSpesolimab·Prednisolone·Prednisone

LEO Pharma

Phase 3

Barcelona, Madrid, Málaga

2025-02-05

By invitation

A Multicenter, International, Prospective and Retrospective, Follow-up Registry to Monitor the Efficacy and Safety of the Occlutech Paravalvular Leak Device (PLD) in Patients With Mitral or Aortic Paravalvular Leaks

NCT07037446Paravalvular Leak

Occlutech International AB

Observational

200

Barcelona

2025-02-05

Recruiting

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

NCT06651970Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment

DrugAcalabrutinib

AstraZeneca

Phase 4

Barcelona, Madrid, Seville

2025-02-04

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT06618287Lung Cancer, Breast Cancer

DrugsPumitamig·Iza-bren·Osimertinib·Opdivo

Bristol-Myers Squibb

Phase 1/2

416

Santiago de Compostela, Barcelona, Hospitalet, Madrid, Majadahonda, Valencia, Málaga, Seville

2025-02-04

Recruiting

Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

NCT06431633Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma

DrugsZimberelimab·Sacituzumab Govitecan·Paraplatin·Cisplatin

Fundación GECP

Phase 3

129

Alicante, Elche, Badalona, Barcelona, L'Hospitalet de Llobregat, Bilbao, Jerez de la Frontera, A Coruña

2025-02-04

Active, closed

Quantification Tools for a Novel Tau PET Marker in a Rare Neurological Disease: 18F-PI-2620 in Progressive Supranuclear Palsy

NCT07105384Parkinson Disease

Fundacion Clinic per a la Recerca Biomédica

Phase 2

Barcelona

2025-02-04

Recruiting

Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)

NCT06897839Bronchopulmonary Dysplasia

Airway Therapeutics, Inc.

Phase 2/3

366

Alicante, Barcelona, Bilbao, Cadiz, Lleida, Madrid, Málaga, Santiago de Compostela

2025-02-03

Active, closed

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

NCT06812325Thyroid Eye Disease (TED)

DrugVRDN-003

Viridian Therapeutics, Inc.

Phase 3

320

A Coruña, Barcelona, Córdoba, Madrid, Navarrés, Seville, Zaragoza

2025-02-03

Recruiting

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

NCT06712355Extensive-stage Small-cell Lung Cancer

DrugsPumitamig·Etoposide·Atezolizumab·Carboplatin

BioNTech SE

Phase 3

621

Badajoz, Barcelona, Castellon, León, Madrid, Málaga, Seville, Torrejón de Ardoz

2025-02-03

Recruiting

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

NCT06556563Glioblastoma

DrugsTemozolomide·Keytruda·Pembrolizumab

NovoCure GmbH

Phase 3

741

Madrid, Barcelona, Córdoba, Granada, Seville, Valencia

2025-02-03

Active, closed

The engAGE Project: Immersive Intergenerational Intervention to Improve Movement in Older Adults

NCT07112638Frailty at Older Adults

University Ramon Llull

Not applicable

240

Barcelona

2025-02-03

Recruiting

Wound Healing and Patient-Reported Outcomes After Gingival Graft Harvesting From the Palate

NCT06806111Palatal Wound

Universitat Internacional de Catalunya

Not applicable

Barcelona

2025-02-03

Recruiting

Study to Assess the Safety and Effectiveness of Beltaven® in Patients With Allergy to Apis Mellifera, Polistes Dominula or Vespula Spp.

NCT07309822Allergy

Probelte Pharma S.L.U.

Observational

Barcelona, Castellon, Ciudad Real, Córdoba, Girona, Lleida, Madrid, Orihuela

2025-02-01

Recruiting

Follow-up of Spanish Prospective Asthma and Nasal Polyposis Registry

NCT06163807Chronic Asthma

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Observational

1,200

Santiago de Compostela, Badalona, Barcelona, A Coruña, Madrid, Pamplona

2025-02-01

Not yet open

Prevention of Postsurgical Chronic Pain in Children and Adolescents (PREVENDOL)

NCT06638437Chronic Postsurgical Pain, Chronic Post-surgical Pain, Chronic Postoperative Pain, Chronic Post-operative Pain

University Rovira i Virgili

Not applicable

125

Barcelona, Madrid, Tarragona

2025-02-01

By invitation

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06679881Hereditary Angioedema (HAE)

DrugDeucrictibant

Pharvaris Netherlands B.V.

Phase 3

170

Barcelona

2025-02-01

Recruiting

Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET)

NCT06896617Infertilities, Embryo Transfer

DrugsEstradiol·Progesterone

Fundacion Clinic per a la Recerca Biomédica

Phase 4

334

Barcelona

2025-02-01

Recruiting

Comparison of Two Surgical Techniques for Treatment of Type III Obesity (BMI 40-50 kg/m2): Single Anastomosis Duodenoileal Bypass With Sleeve Gastrectomy and Roux-en-Y Gastric Bypass.

NCT06789965Obesity

Hospital Clinic of Barcelona

Not applicable

450

Barcelona

2025-02-01

By invitation

Understanding Mechanisms of Synaptic Degeneration Underlying Clinical Symptoms in Patients With MDs and NDs.

NCT07234851Schizophrenia Disorder, Frontotemporal Dementia, Behavioral Variant, Major Depressive Disorder (MDD), Bipolar Disorder (BD)

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Observational

150

Barcelona

2025-02-01

Active, closed

Exploring Eye Vergence Markers ADHD) and ASD

NCT06885060Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD)

Elizabeth Kilbey

Observational

200

Barcelona

2025-02-01

Active, closed

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

588

Cadiz, Badalona, Sabadell, Barcelona, Manises, Valencia, Madrid

2025-01-31

Recruiting

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma

DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin

AstraZeneca

Phase 1/2

408

Barcelona, Madrid, Palma de Mallorca, Santiago de Compostela, Valencia

2025-01-30

Recruiting

NORA-HOME: An Ambulatory Multimodal Monitoring Model In Patients With Minor Stroke And Transient Ischemic Attacks

NCT07500116Stroke (CVA) or TIA, Stroke Recurrence

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

250

Barcelona

2025-01-29

Active, closed

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer

DrugM9140

EMD Serono Research & Development Institute, Inc.

Phase 1/2

184

Córdoba, Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pozuelo de Alarcón, Seville, Valencia

2025-01-29

Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsFicerafusp alfa·Keytruda·Pembrolizumab

Bicara Therapeutics

Phase 2/3

650

Badalona, Barcelona, Madrid, Pamplona, Santander, Valencia

2025-01-28

Recruiting

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

NCT06767683Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia

DrugALKS 2680

Alkermes, Inc.

Phase 2/3

786

Madrid, Barcelona

2025-01-27

Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347Diffuse Large B-Cell Lymphoma

DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience

Merck Sharp & Dohme LLC

Phase 3

1,046

Seville, L'Hospitalet de Llobregat, Barakaldo, Las Palmas de Gran Canaria, Majadahonda, Gijón, Alicante, Barcelona

2025-01-27

Recruiting

Trial Comparing Cataract Surgery With Triple-DMEK in Patients With Cataract and Fuchs Endothelial Corneal Dystrophy

NCT06425666Cataract Surgery, Cataract and Fuchs Endothelial Corneal Dystrophy

University of Cologne

Not applicable

120

Barcelona

2025-01-24

Recruiting

Performance and Safety of Lyoplant® in Guided Bone Regeneration (GBR) in Oral Surgery

NCT06732167Bone Regeneration

Aesculap AG

Not applicable

Barcelona, Sant Cugat Del Vallés

2025-01-24

Active, closed

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

NCT06478212IDH1-mutant Glioma, IDH2-mutant Glioma

DrugsVorasidenib·Temozolomide

Institut de Recherches Internationales Servier

Phase 1/2

Barcelona, Madrid

2025-01-22

Recruiting

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774Chronic Graft-versus-host-disease

DrugsAxatilimab·Methylprednisolone·Prednisolone·Prednisone

Incyte Corporation

Phase 3

240

Barcelona, Donostia / San Sebastian, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Salamanca, Seville

2025-01-21

Recruiting

Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia

NCT04084795Fibromyalgia, Psychological Trauma, Depressive Symptoms, Anxiety

Parc de Salut Mar

Not applicable

Barcelona

2025-01-21

Active, closed

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

NCT06632951Urothelial Carcinoma

DrugsLivmoniplimab·Budigalimab·Docetaxel·Gemcitabine

AbbVie

Phase 2

150

Barcelona, Madrid, Seville

2025-01-20

Recruiting

Intraoperative Ultrasound in Bowel Deep Endometriosis

NCT06876376Deep Infiltrating Endometriosis With or Without Bowel Involvement

Fundacion Dexeus

Observational

200

Barcelona

2025-01-20

Active, closed

Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer

NCT06612203Advanced Breast Cancer

DrugSacituzumab Govitecan

MedSIR

Phase 1/2

Barcelona, Granada, Madrid, Málaga, Valencia

2025-01-17

Recruiting

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

NCT06680830Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)

Neuron23 Inc.

Phase 2

150

San Sebastián, Barakaldo, Barcelona, Madrid, Móstoles, Seville

2025-01-17

Recruiting

Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)

NCT06630611Melanoma, Non Small Cell Lung Cancer, Cervical Cancer

DrugAldesleukin

Vall d'Hebron Institute of Oncology

Phase 2

Barcelona

2025-01-15

Active, closed

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

NCT06684847Primary Sjogrens Disease

DrugEfgartigimod PH20

argenx

Phase 3

631

Vitoria-Gasteiz, Badajoz, Barcelona, Santiago de Compostela, Madrid, A Coruña, Seville, Valencia

2025-01-15

Recruiting

Effectiveness of a Multidisciplinary Treatment for Patients With Chronic Low Back Pain

NCT06679205Chronic Low-back Pain (cLBP), Chronic Low-back Pain, Back Pain

University of Barcelona

Not applicable

Barcelona

2025-01-14

Recruiting

Multimodal Prehabilitation Program That Combines Physical Exercise, Psychological Intervention and Nutritional Support to Improve the Response to Neoadjuvant Chemoterhapy in Early Breast Cancer Patients

NCT07107594Breast Cancer Early Stage Breast Cancer (Stage 1-3), Prehabilitation

Hospital Clinic of Barcelona

Not applicable

214

Barcelona

2025-01-14

Active, closed

A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

NCT06618001Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms

Janssen Research & Development, LLC

Phase 1

Barcelona, Madrid, Pamplona

2025-01-14

Recruiting

Efficacy and Safety of a New Sperm Capacitation Method

NCT06742437Reproductive Issues, Male Infertility, Asthenozoospermia, Oligozoospermia

Fecundis Lab SL

Observational

300

Barcelona

2025-01-14

Active, closed

Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC

NCT06219317NSCLC Stage IV

DrugCemiplimab

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

136

Barcelona, Seville

2025-01-14

Active, closed

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)

DrugOcrelizumab

Amgen

Phase 3

152

Alcorcón, Barcelona, Castilleja de la Cuesta, DÃ©nia, Madrid, Malag, Málaga, Salt

2025-01-13

Recruiting

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

NCT06589596Advanced Solid Tumor

DrugBGB-58067

BeOne Medicines

Phase 1

525

Barcelona, Madrid

2025-01-10

Recruiting

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

NCT06609226Sickle Cell Disease, Thalassemia

Novo Nordisk A/S

Phase 3

480

Barakaldo, Barcelona, Madrid

2025-01-10

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

NCT06754462Rheumatoid Arthritis

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

120

Barcelona, Bilbao, Málaga, Seville

2025-01-10

Active, closed

Pre-Symptomatic Detection of Impending Decompensation in Heart Failure Through Voice Data

NCT07443969Heart Failure, Chronic Heart Failure, Chronic Heart Disease

Noah Labs

Observational

123

Barcelona

2025-01-09

Active, closed

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis

Alumis Inc

Phase 3

1,680

Alicante, Barcelona, Madrid, A Coruña, Manises

2025-01-08

Recruiting

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

NCT06712316Non-small Cell Lung Cancer

DrugsPumitamig·Pemetrexed·Paclitaxel·Carboplatin

BioNTech SE

Phase 2/3

1,580

A Coruña, Badajoz, Badalona, Barcelona, Castellon, Las Palmas de Gran Canaria, León, Lleida

2025-01-07

Recruiting

Physiologic Effects of Continuous Positive Airway Pressure and High Flow Nasal Oxygenation in Patients with Acute Respiratory Distress Syndrome.

NCT06694311Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Failure with Hypoxia

Ricard Mellado Artigas

Not applicable

120

Barcelona

2025-01-07

Active, closed

A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

NCT06764186Locally Advanced or Metastatic Breast Cancer

DrugsCapivasertib·Fulvestrant

AstraZeneca

Phase 3

101

Alicante, Barcelona, Bilbao (Vizcaya), Córdoba, Donostia / San Sebastian, El Palmar, Girona, Madrid

2025-01-07

Active, closed

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637Breast Cancer

DrugsAtirmociclib·Abemaciclib·Ribociclib·Palbociclib

Pfizer

Phase 3

1,035

A Coruña, Elche, Seville, Barcelona, L'Hospitalet de Llobregat, Eixample, Bilbao, Jerez de la Frontera

2025-01-06

Active, closed

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

NCT06660654Advanced Solid Tumor, Metastatic Solid Tumors

DrugR-DXd

Daiichi Sankyo

Phase 2

335

A Coruña, Barcelona, Madrid, Málaga

2025-01-06

Recruiting

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT06588478Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugPirtobrutinib

Loxo Oncology, Inc.

Phase 2

249

Barcelona, L'Hospitalet Del Llobregat, Madrid, Majadahonda, Marbella, Oviedo, Salamanca, Santander

2025-01-03

Recruiting

Zn Supplementation in HIV Immunological Non Responders

NCT06612554HIV, Zinc Status, HIV Infection

Parc de Salut Mar

Not applicable

120

Barcelona

2025-01-02

Recruiting

Precision Medicine for L/GCMN and Melanoma 2

NCT06605443Melanoma (Skin Cancer), Nevi and Melanomas, Congenital Melanocytic Nevus

Fundacion Clinic per a la Recerca Biomédica

Observational

100

Barcelona

2025-01-01

Recruiting

Risk Score of Embolism in Patients With AF Undergoing DOAC Therapy

NCT07713537Atrial Fibrillation (AF), Ischemic Stroke

Hospital Universitari Vall d'Hebron Research Institute

Observational

250

Barcelona

2025-01-01

Recruiting

Clinical and CPET Parameters That Predict Improvement in Functional Capacity After TAVI

NCT06833762Aortic Stenosis Disease

Hospital Clinic of Barcelona

Observational

161

Barcelona

2025-01-01

Recruiting

Left Septal Pacing or Left Bundle Branch Pacing to Avoid Left Ventricle Systolic Dysfunction

NCT06707662AV Block

Parc de Salut Mar

Not applicable

150

Barcelona

2025-01-01

Active, closed

Tissue Characterization in STEMI Using Cardiac MRI: a Multicenter Registry

NCT07291999Ischemic Cardiovascular Disease, Magnetic Resonance

Fundación para la Investigación del Hospital Clínico de Valencia

Observational

500

Barcelona, Valencia

2025-01-01

Active, closed

A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain

NCT06746116Advanced or Recurrent Endometrial Cancer

DrugDurvalumab

AstraZeneca

Phase 3

A Coruña, Alicante, Barakaldo, Barcelona, Córdoba, El Palmar, Girona, L'Hospitalet de Llobregat

2024-12-30

Not yet open

Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant

NCT05982275Multiple Myeloma, Allogeneic Stem Cell Transplantation

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 1/2

Santander, Barcelona, Salamanca, Seville, Valencia

2024-12-30

By invitation

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

NCT06788509Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes

DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543·Ibrutinib

Janssen Research & Development, LLC

Phase 1

120

Barcelona, Madrid, Pamplona, Salamanca

2024-12-30

Active, closed

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

NCT06687369Non Squamous Non Small Cell Lung Cancer

DrugsEU sourced Keytruda·US-sourced Keytruda·Pemetrexed·Cisplatin

mAbxience Research S.L.

Phase 3

726

A Coruña, Barcelona, Madrid, Málaga, Murcia, Oviedo, Palma de Mallorca, Pontevedra

2024-12-30

Recruiting

MamaConecta: Digital Tool for Maternal Mental Health

NCT06442774Pregnancy Related, Mental Health Issue, Postpartum Depression, Postpartum Anxiety

A Thousand Colibris, S.L

Not applicable

1,200

Barcelona, Tarragona

2024-12-28

Recruiting

A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma

NCT06650514Osteosarcoma, Osteosarcoma in Children

DrugOMO-103

Vall d'Hebron Institute of Oncology

Phase 2

Barcelona

2024-12-27

Recruiting

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

NCT06078384Triple-negative Breast Cancer

DrugsTaxol·Keytruda·Paclitaxel·Pembrolizumab

UNICANCER

Phase 2

354

Alicante, Badalona, Barcelona, El Palmar, Granada, L'Hospitalet de Llobregat, León, Lleida

2024-12-27

Recruiting

Early Transcatheter Mitral Valve Repair After Myocardial Infarction

NCT06282042Acute Mitral Regurgitation

Fundación para la Investigación Biosanitaria del Principado de Asturias

Not applicable

250

Alicante, Barcelona, L'Hospitalet de Llobregat, Santander, Córdoba, Las Palmas de Gran Canaria, Madrid, Málaga

2024-12-24

Active, closed

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

NCT06604715Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

Phase 1

Badalona, Barcelona, Madrid, Pamplona, Salamanca

2024-12-19

Active, closed

A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis

NCT06752850Haemophilia A (Moderate or Severe), Hemophilia, Classic, Haemophilia, Hemophilia

DrugEfanesoctocog alfa

Swedish Orphan Biovitrum

Phase 4

Barcelona, Madrid, Seville, Valencia

2024-12-19

Recruiting

REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization

NCT06922175Epilepsy With Uncontrolled Focal-onset Seizures

Aziende Chimiche Riunite Angelini Francesco S.p.A

Observational

200

Barcelona, Madrid, Valencia

2024-12-19

Recruiting

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion

DrugsBrivekimig·Frexalimab·Rilzabrutinib

Sanofi

Phase 2

Seville, Barcelona, Córdoba, Madrid

2024-12-19

Recruiting

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction

Cytokinetics

Phase 3

1,800

A Coruña, Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Úbeda, Lugo, Madrid, Majadahonda

2024-12-19

Active, closed

Trustworthy Artificial Intelligence for Improvement of Stroke Outcomes

NCT06710028Stroke, Acute, Stroke, Ischemic, Stroke

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Observational

1,000

Barcelona

2024-12-18

Active, closed

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

NCT06742190Multifocal Motor Neuropathy (MMN), MMN

DrugsEmpasiprubart·Immunoglobulin·IVIG

argenx

Phase 3

154

Alicante, Badalona, Barcelona, Madrid, Málaga, San Sebastián

2024-12-18

Recruiting

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

NCT06423573Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional

Chiesi Farmaceutici S.p.A.

Observational

170

Barcelona

2024-12-18

Recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT06727604Graves' Disease

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

240

Badalona, Barcelona, Córdoba, Granada, Madrid, Pamplona, Seville

2024-12-17

Active, closed

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

NCT06665256Idiopathic Inflammatory Myopathies

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca

2024-12-17

Active, closed

Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2

NCT06672445Spinocerebellar Ataxia Type 2

Arrowhead Pharmaceuticals

Phase 1

Barcelona, Seville

2024-12-17

Recruiting

DEBSCAN-IVL. Drug Eluting Balloon or Drug Eluting Stent to Treat CAlcified Nodules After IntraVascular Lithotripsy.

NCT06657833Coronary Artery Disease

Fundación EPIC

Not applicable

128

Barcelona, Fuencarral-El Pardo, Galdakao, L'Hospitalet de Llobregat, León, Madrid, Moncloa-Aravaca, Pamplona

2024-12-17

Recruiting

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

NCT06747585Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma

Alentis Therapeutics AG

Phase 1/2

170

PAU de Sanchinarro, Pozuelo de Alarcón, Barcelona, Madrid, Málaga, Seville, Valencia

2024-12-16

Recruiting

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma

DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone

GlaxoSmithKline

Phase 3

520

Badalona, Barcelona, Gijón, Madrid, Málaga, Murcia, Salamanca, Santander

2024-12-16

Recruiting

The PERSEVERE Study

NCT06588634Pulmonary Embolism, Pulmonary Thromboembolism

Inari Medical

Not applicable

200

Barcelona, Madrid

2024-12-16

Recruiting

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

NCT06784193Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer

DrugsPalazestrant·Fulvestrant

Olema Pharmaceuticals, Inc.

Phase 1

180

Barcelona, Madrid

2024-12-16

Recruiting

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

NCT06501625Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

DrugsIvosidenib·Durvalumab·Gemcitabine·Cisplatin

Institut de Recherches Internationales Servier

Phase 1/2

Barcelona, Madrid

2024-12-16

Recruiting

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab

Janssen Research & Development, LLC

Phase 2

480

Barcelona, Jerez de la Frontera, Madrid, Santiago de Compostela, Valencia

2024-12-16

Active, closed

Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

NCT06668558Acute Myeloid Leukemia

DrugsAzacitidine·Venetoclax

Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias

Phase 2

Palma de Mallorca, Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Lleida, Tarragona, Terrassa

2024-12-16

Not yet open

Submerged Vs Non-Submerged Guided Bone Regeneration Simultaneous to Implant Placement.

NCT06695338Guided Bone Regeneration, Dental Implant, Submerged Regeneration, Bone Atrophy

Universitat Internacional de Catalunya

Not applicable

Barcelona

2024-12-15

Recruiting

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC

Gilead Sciences

Phase 1/2

250

Barcelona, Madrid

2024-12-13

Active, closed

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

NCT06710847Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer

GlaxoSmithKline

Phase 1/2

Barcelona, Madrid, Málaga

2024-12-13

Recruiting

Phase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents

NCT06745557Burns

DrugsDenovoSkin·Ehsg-Kf

CUTISS AG

Phase 3

Barcelona, Madrid, Valencia

2024-12-13

Active, closed

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT06608927Metastatic Pancreatic Ductal Adenocarcinoma

DrugsQuemliclustat·Nab-paclitaxel·Gemcitabine

Arcus Biosciences, Inc.

Phase 3

610

Barcelona, Elche, Girona, Madrid, Pamplona, Vigo, Zaragoza

2024-12-13

Active, closed

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

NCT06675864Progressive Multiple Sclerosis

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 1/2

Barcelona, Madrid, Málaga

2024-12-12

Recruiting

A Multicenter, Open, Comparative Study on Vaginal Dysbiosis in Premenopausal Women (DISPALOMA)

NCT06668012Vaginal Dysbiosis

Procare Health Iberia S.L.

Not applicable

Barcelona, Madrid

2024-12-12

Recruiting

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

NCT06716606Connective Tissue Diseases

DrugBelimumab

GlaxoSmithKline

Phase 3

514

Bilbao, Barcelona, VigoPontevedra

2024-12-12

Recruiting

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT06750094Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Avastin

Janssen Research & Development, LLC

Phase 3

700

Badajoz, Barcelona, Madrid, Málaga, Pamplona, Seville, Valencia

2024-12-12

Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858Candidemia, Candidiasis, Invasive

DrugsCaspofungin·Fosmanogepix·Fluconazole

Basilea Pharmaceutica

Phase 3

450

Seville, Barcelona, Madrid, Barakaldo

2024-12-11

Active, closed

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

NCT06734234Kidney Disease

DrugGSK4771261

GlaxoSmithKline

Phase 1

Barcelona, Madrid

2024-12-11

Active, closed

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

NCT06784648Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent

DrugsIpilimumab·Keytruda·Pembrolizumab

BioInvent International AB

Phase 1/2

Barcelona, Madrid

2024-12-11

Recruiting

Tacrolimus Minimization in Kidney Transplant Recipients Selected According to the AGORA Algorithm for Their Low Immunological Risk and Medium-term Graft Failure

NCT06235892Organ Grafts

DrugTacrolimus

Nantes University Hospital

Phase 3

300

Barcelona

2024-12-10

Not yet open

Evaluation of Cardioverter Capacity of Amiodarone Pre-electrical Cardioversion in Persistent Atrial Fibrillation

NCT06645249Atrial Fibrillation (AF)

DrugAmiodarone

Institut Investigacio Sanitaria Pere Virgili

Phase 4

122

Badalona, Barcelona, Reus, Santiago de Compostela

2024-12-10

Recruiting

The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy

NCT06282809Pancreas Cancer, Adenocarcinoma of the Pancreas, Pancreatic Cancer, Tumor of Pancreas

HistoSonics, Inc.

Not applicable

Barcelona

2024-12-10

By invitation

Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

NCT06723106Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)

DrugRAY121

Chugai Pharmaceutical

Phase 1

144

Pamplona, Madrid, Barcelona, Córdoba, Seville, Valencia

2024-12-09

Recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019Familial Hypercholesterolemia - Heterozygous

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

Elche, Cadiz, Badalona, Esplugues, Pamplona, Barcelona, Málaga, Seville

2024-12-09

Active, closed

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984Metastatic Castration-resistant Prostate Cancer

DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide

Amgen

Phase 3

707

Málaga, Seville, Barcelona, Pamplona, Valencia, Madrid

2024-12-09

Recruiting

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

NCT06679140COVID-19 SARS-CoV-2 Infection

DrugIbuzatrelvir

Pfizer

Phase 3

2,330

A Coruña, Benalmádena, Córdoba, Badalona, Barcelona, Madrid, Vigo, Alicante

2024-12-08

Recruiting

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

NCT06534437Non-Hodgkin Lymphoma, B-cell

DrugGlofitamab

Ryvu Therapeutics SA

Phase 2

178

Barcelona, Madrid, Murcia, Pamplona, Salamanca, Seville, Zaragoza

2024-12-05

Recruiting

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

NCT06382948Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation

DrugsElacestrant·Everolimus

MedSIR

Phase 3

300

Barcelona, A Coruña, Alicante, Badalona, Bilbao, Burgos, Castellon, Cáceres

2024-12-05

Active, closed

A Long-term Safety and Efficacy Study of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Subjects With Acne Vulgaris (GEDACNE-LT)

NCT07389109Acne Vulgaris

PPM Services S.A.

Phase 3

400

Alcorcón, Barcelona, Esplugues de Llobregat, Granada, Madrid, Málaga, Seville, Valencia

2024-12-05

Recruiting

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

NCT06768489Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis

DrugsRamantamig·Pomalidomide·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 1

276

Barcelona, Salamanca

2024-12-04

Active, closed

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969Sjogrens Syndrome

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

655

Barcelona, Huelva, Madrid, Pamplona, Santander, Seville

2024-12-04

Active, closed

A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

NCT06706817Chronic Rhinosinusitis With Nasal Polyps

AstraZeneca

Phase 3

181

Barcelona, Cadiz, Madrid, Salamanca, Santiago de Compostela

2024-12-03

Recruiting

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

NCT06465953Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)

DrugsIvosidenib·Azacitidine

Institut de Recherches Internationales Servier

Phase 3

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia

2024-12-03

Recruiting

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

NCT06180356Ovarian Cancer, Oligometastatic Disease, Serous Ovarian Tumor

DrugNiraparib

MedSIR

Phase 2

A Coruña, Barakaldo, Barcelona, Girona, Jaén, Madrid, Málaga, Oviedo

2024-12-03

By invitation

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugVutrisiran

Alnylam Pharmaceuticals

Phase 3

700

Barcelona, Bilbao, L'Hospitalet de Llobregat, Madrid, Málaga

2024-12-03

Active, closed

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

NCT06706622Multiple System Atrophy

DrugAmlenetug

H. Lundbeck A/S

Phase 3

401

Barcelona, Barcelona (Spain), Madrid, Seville, Valencia

2024-12-03

Active, closed

Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)

NCT06617429Angelman Syndrome

DrugApazunersen

Ultragenyx Pharmaceutical Inc

Phase 3

129

Barcelona, Madrid, Seville

2024-12-03

Recruiting

Image-Based Prediction of Ventricular Tachycardias in Post-Myocarditis Patients: an International Multicenter Case-control Study

NCT06730607Myocarditis, Ventricular Arrhythmia

Centro Medico Teknon

Observational

150

Barcelona

2024-12-02

Recruiting

Validation of the MaiRa Preeclampsia Test for Screening Early/Late Preeclampsia in First and Second Trimesters

NCT06716242Preeclampsia (PE)

iPremom

Observational

7,473

Alicante, Barcelona, Vinaròs, Cadiz, A Coruña, Torrejón de Ardoz, El Palmar, San Cristóbal de La Laguna

2024-12-02

Recruiting

Modulation of the Inflammatory Response in Bariatric Surgery

NCT06915558Obesity, Bariatric Surgery Candidate, Inflammation, Postoperative Pain

Hospital HM Nou Delfos

Observational

Barcelona

2024-12-02

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

NCT06717698Chronic Kidney Disease

DrugSemaglutide

Novo Nordisk A/S

Phase 2

465

Barcelona, Córdoba, Getafe, L'Hospitalet de Llobregat, Madrid, Seville, Valencia

2024-12-02

Recruiting

Analysis of Dietary Intake in Professional Female Football Players

NCT06713954Dietary Assessment

University Ramon Llull

Observational

100

Barcelona

2024-12-02

Recruiting

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

NCT06667700Coronavirus Disease (COVID-19)

DrugMolnupiravir

Merck Sharp & Dohme LLC

Phase 3

3,082

Elche, Badalona, Centelles, Barcelona, A Coruña, Cartagena, Madrid, Seville

2024-12-02

Active, closed

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805HIV Infections

DrugsRpv La·B/F/TAF·Cabotegravir

ViiV Healthcare

Phase 3

326

L'Hospitalet de Llobregat, Bilbao, Puerto Real, Barcelona, Córdoba, Madrid, Málaga, Murcia

2024-12-02

Recruiting

Evaluation of heepSync, a Novel Algorithm for Transcutaneous Electrical Stimulation of Respiratory Muscles in Mechanically Ventilated Patients.

NCT07363902Ventilator-induced Diaphragm Dysfunction, VIDD, Weaning Failure

Tesai Care SL

Not applicable

Barcelona, L'Hospitalet de Llobregat, Sabadell

2024-12-01

By invitation

PIECES - Towards Large-Scale Adaptation and Tailored Implementation of Primary Cancer Prevention Programs

NCT06718322Focus of Study: Tailored Implementation

Hidde van der Ploeg

Not applicable

100

Barcelona

2024-12-01

Active, closed

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06669754Hereditary Angioedema (HAE)

DrugDeucrictibant

Pharvaris Netherlands B.V.

Phase 3

Barcelona, Seville

2024-12-01

Recruiting

Artificial Intelligence Satisfaction in Professionals and Patients

NCT06726447General Health Status

Universidad Autonoma de Madrid

Not applicable

148

Barcelona, Madrid

2024-12-01

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

NCT06627647Non-squamous Non-small Cell Lung Cancer

DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin

AstraZeneca

Phase 3

1,160

Barcelona, Castellon, Las Palmas de Gran Canaria, Madrid, Majadahonda, Seville

2024-11-27

Recruiting

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)

DrugSurovatamig

AstraZeneca

Phase 2

270

Barcelona, Madrid, Pozuelo de Alarcón

2024-11-27

Active, closed

Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

NCT06543914Migraine

AbbVie

Observational

1,314

Málaga, L'Hospitalet de Llobregat, Leganés, Majadahonda, Oviedo, Seville, Barcelona, Madrid

2024-11-26

Recruiting

Validation of a Regional Citrate Anticoagulation Protocol in Critically Ill Patients on Continuous Renal Replacement Therapy

NCT07514650Acute Kidney Injury, ICU Patients, Continuous Renal Replacement Therapy (CRRT), Electrolytes

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Not applicable

Barcelona

2024-11-24

Recruiting

Clinical Impact of Uterine Repair During Cesarean Section with Barbed Suture on the Incidence of Isthmocele

NCT06691750Isthmocele, Cesarean Scar Defect, Pelvic Pain, Spotting

Hospital Clinic of Barcelona

Not applicable

364

Barcelona

2024-11-22

Recruiting

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT05552157Alzheimers Disease, Dementia, Alzheimers Disease, Familial

DrugRemternetug

Washington University School of Medicine

Phase 2/3

280

Barcelona

2024-11-22

Recruiting

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT06647498Alzheimers Disease, Dementia, Alzheimers Disease, Familial

DrugRemternetug

Washington University School of Medicine

Phase 2/3

280

Barcelona

2024-11-22

Recruiting

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

NCT06532006Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer

DrugsHLX22·Trastuzumab·Capecitabine·Oxaliplatin

Shanghai Henlius Biotech

Phase 3

550

Barcelona, Madrid, Majadahonda, Oviedo, Seville, Valencia, Vigo

2024-11-22

Active, closed

A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)

NCT06698042Lung Cancer, Non-Small Cell Lung Cancer

Drugs) Berahyaluronidase alfa·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

Donostia / San Sebastian, Barcelona, Huelva, Seville

2024-11-21

Recruiting

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

NCT06458712Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)

Duke Street Bio Ltd

Phase 1

180

Logroño, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia

2024-11-21

Recruiting

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325Systemic Lupus Erythematosus

UCB Biopharma SRL

Phase 3

450

A Coruña, Badajoz, Barcelona, Castellon, Madrid, Málaga, Mérida, Sabadell

2024-11-21

Recruiting

Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma

NCT07254754DIFFUSE LARGE B-CELL LYMPHOMA

DrugAxicabtagene Ciloleucel

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2

A Coruña, Palma de Mallorca, Santander, Salamanca, Barcelona, L'Hospitalet de Llobregat, San Sebastián, Las Palmas de Gran Canaria

2024-11-20

Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

NCT06369285Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer

DrugAlisertib

Puma Biotechnology, Inc.

Phase 2

225

Alicante, Barakaldo, Barcelona, Bilbao, Cáceres, Granada, Huelva, Jaén

2024-11-19

Active, closed

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247Leukemia

DrugQuizartinib

Daiichi Sankyo

Phase 3

700

Albacete, Alicante, Badalona, Barcelona, Burgos, Cáceres, Córdoba, Las Palmas

2024-11-19

Active, closed

Improving Patient Safety by Supporting Older Adults in Managing Sleep Problems.

NCT06584513Benzodiazepines Deprescribing, Sleep Problems

Insel Gruppe AG, University Hospital Bern

Not applicable

470

Barcelona

2024-11-18

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738Non-small Cell Lung Cancer

DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel

AstraZeneca

Phase 3

1,160

Barcelona, Las Palmas de Gran Canaria, Lleida, Madrid, Majadahonda, Seville

2024-11-18

Recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

NCT06672549Obesity, Overweight

DrugOrforglipron

Eli Lilly and Company

Phase 3

125

Barcelona, Madrid, Málaga, Sabadell, Seville, Vitoria-Gasteiz

2024-11-18

Active, closed

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

NCT06616194Migraine

DrugRimegepant

Pfizer

Phase 3

200

Barcelona, Madrid, Vigo, Seville, Valencia, Valladolid

2024-11-15

Not yet open

Effects of Ultrasound-guided Maxillary Nerve Block Performed After Bimaxillary Osteotomy in Adult Patients

NCT06460051Maxillary Diseases, Pain, Postoperative, Adult Patients Undergoing Bimaxillary Osteotomy

Servei Central d'Anestesiologia

Not applicable

Barcelona

2024-11-15

By invitation

Pharmaceutical Literacy and Quality of Life in Spanish Population.

NCT06729697Health Related Quality of Life, Literacy

University of Barcelona

Observational

1,246

Barcelona

2024-11-15

Recruiting

The Interplay Between Inborn Error of Immunity and Blood Disorders: Unravelling Immune Defects Behind Common Haematological Diseases

NCT06857604Hematologic Diseases

Meyer Children's Hospital IRCCS

Not applicable

700

Barcelona

2024-11-15

Not yet open

Maxillary and Mandibular Nerve Block. Block One Get One Free.

NCT06599138Postoperative Pain, Regional Anesthesia Morbidity

Servei Central d'Anestesiologia

Not applicable

Barcelona

2024-11-14

Active, closed

Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain

NCT06415175Atopic Dermatitis

DrugDupilumab

Sanofi

Observational

143

Santiago de Compostela, Esplugues de Llobregat, Oviedo, Seville, Alicante, Barcelona, Madrid, Málaga

2024-11-14

Recruiting

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

NCT06619587Solid Tumor

Genentech, Inc.

Phase 1

410

Barcelona, Madrid, Málaga, Seville, Valencia

2024-11-14

Active, closed

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

NCT06637501Chronic Lymphocytic Leukemia

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 2

Barcelona, Gijón, Madrid

2024-11-14

Recruiting

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

NCT06632457Metabolic Dysfunction Associated Steatohepatitis

Boehringer Ingelheim

Phase 3

1,590

A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Pontevedra, Santiago de Compostela

2024-11-12

Active, closed

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

NCT06719141Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

367

Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga, Valencia

2024-11-11

Recruiting

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

NCT06655155Systemic Sclerosis (SSc)

argenx

Phase 2

Barcelona, Córdoba, Sabadell

2024-11-11

Active, closed

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

283

Barcelona, León, Madrid, Salamanca, Santander, Valencia

2024-11-11

Recruiting

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

NCT06531499Metastatic Castration-Resistant Prostate Cancer

DrugLu-PSMA

Novartis Pharmaceuticals

Phase 1

106

Santiago Compostela, Majadahonda, Barcelona

2024-11-11

Recruiting

Prospective Evaluation of Atrial Fibrillation-Related Stroke Patients in Rehabilitation Program (PEARL), an Observational Cohort Study

NCT07253974STROKE, Rehabilitation Outcome, Brain Disease, Cardiovascular Disease Acute

Parc de Salut Mar

Observational

213

Barcelona

2024-11-11

Recruiting

Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT06648096Fanconi Anemia, Head and Neck Squamous Cell Carcinoma

DrugAfatinib

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Phase 1/2

Barcelona

2024-11-08

Recruiting

Implementation of a Psychoeducational Intervention in New Mothers

NCT06512025Depression, Postpartum, Anxiety

Alba Roca

Not applicable

400

Barcelona

2024-11-08

Recruiting

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

NCT06659341Advanced Solid Tumors Harboring KRAS G12C Mutation

Bayer

Phase 1

104

Barcelona

2024-11-08

Recruiting

Study of IMC-P115C in Advanced PRAME-Positive Cancers

NCT07156136PRAME Positive, Cancer, HLA-A*02:01-positive

Immunocore Ltd

Phase 1

140

Barcelona, Madrid

2024-11-07

Recruiting

Influence of Vessel Wall Calcification on Early Stent Strut Healing

NCT06631755Coronary Artery Disease

Fundación EPIC

Not applicable

Barcelona

2024-11-07

Active, closed

Abbott Medical - VERITAS Study

NCT06707688Atrial Fibrillation (AF), Stoke

Abbott Medical Devices

Not applicable

458

Barcelona, Madrid, Salamanca

2024-11-07

Active, closed

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319Asthma

DrugsBudesonide/Formoterol·Lunsekimig

Sanofi

Phase 2

556

Santiago de Compostela, Badalona, Santander, Barcelona, Madrid, Benalmádena, Girona, Málaga

2024-11-07

Recruiting

Discovering Adolescents' Talents and Life Projects as a Key Factor in Their Life Satisfaction

NCT06473155Healthy, Adolescent Development

Centre Besai

Not applicable

Barcelona

2024-11-05

Recruiting

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

NCT06298565Myasthenia Gravis

DrugEfgartigimod

argenx

Observational

680

Barcelona, Madrid, Seville

2024-11-04

Active, closed

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

NCT06076642Primary Immunodeficiency Diseases (PID)

DrugTAK-881

Takeda

Phase 3

Barcelona

2024-11-04

Recruiting

Accelerated Flap Coverage in Severe Lower Extremity Trauma

NCT06293469Open Tibia Fracture, Open Dislocation of Ankle, Extremity Fracture Lower, Extremity Injuries Lower

Johns Hopkins University

Not applicable

356

Barcelona

2024-11-04

Active, closed

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

NCT06596694Gastrointestinal Cancer

DrugPatritumab deruxtecan

Merck Sharp & Dohme LLC

Phase 1/2

180

Oviedo, Barcelona, Madrid

2024-11-03

Active, closed

Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia

NCT06695832Staphylococcus Aureus Bacteremia

Hospital Universitari de Bellvitge

Observational

369

L'Hospitalet de Llobregat, Badalona, Barcelona

2024-11-01

Recruiting

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

NCT06456593Moderately to Severely Active Crohn Disease

DrugObefazimod

Abivax S.A.

Phase 2

212

Barcelona, Córdoba, Fuenlabrada, Huelva, Las Palmas de Gran Canaria, Santiago de Compostela, Seville, Valencia

2024-10-30

Active, closed

A Study of ZW191 in Participants With Solid Tumors

NCT06555744Advanced Solid Tumors

Zymeworks BC Inc.

Phase 1

145

Barcelona, Córdoba, Madrid, Valencia

2024-10-30

Recruiting

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

NCT06630806Plasma Cell Myeloma Refractory

Sanofi

Phase 1

Barcelona, Madrid

2024-10-30

Recruiting

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

NCT06541704Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

975

Córdoba, L'Hospitalet de Llobregat, Terrassa, Burjassot, Barcelona, Seville, Valencia, Zaragoza

2024-10-30

Recruiting

International Pilot Study for Dual Non-invasive Assesment of Embryo Development

NCT06524648Infertility

Igenomix

Observational

200

Barcelona, Madrid, Murcia, Seville, Valencia

2024-10-29

Active, closed

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896Scleroderma, Diffuse

DrugsRapcabtagene autoleucel·Rituximab

Novartis Pharmaceuticals

Phase 2

Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca

2024-10-29

Recruiting

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors

DrugsBBO-10203·Ribociclib·Folfox·Fulvestrant

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Phase 1

392

Barcelona, Madrid, Pozuelo de Alarcón, Lleida, Valencia

2024-10-29

Active, closed

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

NCT06413706Glioma

DrugsAbemaciclib·Temozolomide

Eli Lilly and Company

Phase 2

Barcelona, Córdoba, Esplugues de Llobregat, Madrid, Seville, Valencia

2024-10-25

Recruiting

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

NCT06638307Advanced Breast Cancer

DrugElacestrant

Stemline Therapeutics, Inc.

Phase 1

240

Barcelona, Madrid, Valencia

2024-10-25

Recruiting

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110Healthy Volunteers, Pulmonary Arterial Hypertension

Novartis Pharmaceuticals

Phase 1/2

232

Santiago Compostela, Marbella, Toledo, Barcelona, Las Palmas de Gran C, Seville

2024-10-24

Active, closed

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

NCT06602193Parkinson Disease

Denali Therapeutics Inc.

Phase 2

Barcelona, Donostia / San Sebastian, Madrid, Santander, Seville

2024-10-24

Recruiting

Testing Pulse Stimulation to Improve Motor Function in People With ALS: A Pilot Study

NCT06681610Amyotrophic Lateral Sclerosis (ALS)

Parc de Salut Mar

Not applicable

Barcelona

2024-10-24

Active, closed

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

NCT06653153Alzheimer's Disease

DrugRemternetug

Eli Lilly and Company

Phase 3

1,400

Barcelona, Pozuelo de Alarcón, San Sebastián, Seville

2024-10-24

Recruiting

Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT06667960Solid Tumor

Salubris Biotherapeutics Inc

Phase 1/2

255

Barcelona, Madrid, Pamplona, Rioja, Valencia

2024-10-23

Recruiting

DRUG RELEASING BALL vs. PHARMACOACTIVE STENT IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY) IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY)

NCT06448637Coronary Artery Disease

Fundación EPIC

Not applicable

Barcelona, Gijón, Huelva, León, Lugo, Mérida, Oviedo, Pontevedra

2024-10-23

Recruiting

Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome

NCT06681012Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome of Diarrhea Type (IBS-D)

Devintec Sagl

Not applicable

330

Barcelona, Madrid

2024-10-22

Active, closed

A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)

NCT06660563Lymphoma, Non-Hodgkin

DrugsJNJ-75348780·JNJ-80948543

Janssen Research & Development, LLC

Phase 1

Barcelona, L'Hospitalet de Llobregat, Madrid

2024-10-22

Active, closed

Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

NCT06321601Vasculitis

DrugAvacopan

Amgen

Phase 3

Barcelona, Esplugues de Llobregat, Madrid

2024-10-22

Recruiting

The Sagittarius Trial

NCT06490536Colon Cancer Stage II, Colon Cancer Stage III

DrugsFolinic acid·Panitumumab·Pertuzumab·Temozolomide

IFOM ETS - The AIRC Institute of Molecular Oncology

Phase 3

700

Barcelona, Valencia, Córdoba, Madrid, Pamplona, Santander, Santiago de Compostela, Zaragoza

2024-10-22

Active, closed

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)

DrugsMevrometostat·Xtandi·Taxotere·Enzalutamide

Pfizer

Phase 3

600

L'Hospitalet de Llobregat, Barcelona, Madrid, Manresa, Valencia

2024-10-21

Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422Carcinoma, Non-Small-Cell Lung

DrugsIntismeran autogene·Paraplatin·Taxol·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

680

Canarias, A Coruña, Pozuelo de Alarcón, Barcelona, Madrid, Málaga

2024-10-21

Recruiting

Transfer Direct System as a New Method for Embryo Transfer

NCT06744049Embryo Transfer

Premium Fertility

Not applicable

Barcelona, Valencia, Seville

2024-10-21

Recruiting

Changes in Eye Pressure in Glaucoma Patients Treated with Istent Inject W, Monitored by a Contact Lens Sensor

NCT06607705Glaucoma Eye

Fundacio Privada Mon Clinic Barcelona

Not applicable

Barcelona

2024-10-21

Recruiting

ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)

NCT06430385Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

Ionis Pharmaceuticals, Inc.

Phase 1/2

Barcelona

2024-10-21

Active, closed

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor

Drugs5Fluorouracil·Leucovorin·Irinotecan·Cetuximab

Eli Lilly and Company

Phase 1

750

Barcelona, Madrid, Málaga

2024-10-21

Active, closed

Short-term Interruption Versus Continuous Anticoagulation in Colorectal Polypectomy

NCT07185295Anticoagulated Patients

Outcomes'10

Phase 4

481

Palma, Torrelavega, Valladolid, Barcelona, Alcalá de Henares, Madrid, Majadahonda, Avilés

2024-10-18

Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Irinotecan

Janssen Research & Development, LLC

Phase 3

1,000

Barcelona, Madrid, Pamplona, Seville, Valencia

2024-10-18

Active, closed

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

NCT06643481Amyotrophic Lateral Sclerosis (ALS)

DrugVHB937

Novartis Pharmaceuticals

Phase 2

251

Santiago Compostela, L'Hospitalet de Llobregat, Barcelona, Valencia

2024-10-17

Active, closed

Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

NCT05888922Androgenetic Alopecia, Female Pattern Baldness

DrugMinoxidil

Industrial Farmacéutica Cantabria, S.A.

Phase 3

520

Barcelona, Madrid, Valencia

2024-10-17

Recruiting

Aut-CARE Intervention to Improve Cognitive and Emotional Functioning in Young Adults on the Autism Spectrum

NCT07041502Autism Spectrum Disorder, Autism Spectrum Disorder With Absence of Functional Language

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Observational

Barcelona

2024-10-16

Active, closed

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

DrugsLiposomal Irinotecan·Leucovorin·Irinotecan·Cetuximab

Revolution Medicines, Inc.

Phase 3

500

Barcelona, Madrid, Pamplona, Valencia

2024-10-16

Active, closed

A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

NCT06598462Eosinophilic Esophagitis (EoE)

DrugSolrikitug

Uniquity One (UNI)

Phase 2

184

Barcelona, Madrid, Tomelloso

2024-10-16

Recruiting

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer

Novartis Pharmaceuticals

Phase 1

162

Barcelona, Madrid

2024-10-15

Active, closed

RTX001 Autologous Engineered Macrophages for Liver Cirrhosis

NCT06823713End-stage Liver Disease (ESLD), Cirrhosis, Liver, Cirrhosis, Decompensated, Liver Diseases

Resolution Therapeutics Limited

Phase 1/2

Barcelona, Córdoba, Madrid, Seville, Valencia

2024-10-15

Recruiting

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

NCT06663319Colorectal Neoplasms, Gastrointestinal Neoplasms

DrugsFolfox·Bevacizumab

Janssen Research & Development, LLC

Phase 1

260

Barcelona, Madrid

2024-10-15

Not yet open

Adjunctive Use of Polynucleotide and Hyaluronic Acid-based Gel in Alveolar Preservation After Tooth Extraction

NCT06633211Bone Substitutes, Tooth Extraction Status Nos

Adrià Jorba García

Not applicable

Barcelona

2024-10-15

Recruiting

Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

NCT06533813Myelofibrosis

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Observational

617

Barcelona, Madrid

2024-10-14

Recruiting

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis

Boehringer Ingelheim

Phase 3

1,800

A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Pontevedra, Santander, Santiago de Compostela

2024-10-14

Active, closed

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

NCT06447168Primary Biliary Cholangitis

Ipsen

Observational

424

Almería, Barcelona, Madrid, Pontevedra, Santander

2024-10-14

Active, closed

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

NCT06553768Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

DrugMaralixibat

Mirum Pharmaceuticals, Inc.

Phase 3

Barcelona, Madrid

2024-10-14

Active, closed

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT06388564Chronic Graft-versus-host-disease

DrugsAxatilimab·Ruxolitinib·Methylprednisolone·Prednisolone

Incyte Corporation

Phase 2

130

Barcelona, El Palmar, Granada, Granvia de L'hospitalet 199-203, Madrid, Málaga, Salamanca, Santander

2024-10-11

Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

NCT06581432Solid Tumours

DrugZongertinib

Boehringer Ingelheim

Phase 2

588

A Coruña, Badalona, Barcelona, Madrid, Pamplona, Seville, Valencia

2024-10-11

Recruiting

Safety and Effectiveness of Short-Term Single AntiPlatelet Therapy After Left Atrial Appendage Closure With the LAmbre Device in Patients With Nonvalvular Atrial Fibrillation: A Multinational Real-world Registry

NCT06620757Atrial Fibrillation

Fundación EPIC

Observational

234

A Coruña, Aravaca, Barcelona, Córdoba, Fuencarral-El Pardo, Gijón, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria

2024-10-10

Active, closed

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

NCT06516965Prurigo Nodularis

DrugPovorcitinib

Incyte Corporation

Phase 3

346

Alicante, Badalona, Barcelona, Córdoba, Granada, Madrid, Majadahonda, Manises

2024-10-10

Active, closed

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

NCT06625060Episodic Migraine, Chronic Migraine

DrugCorabotase

Ipsen

Phase 2

670

Barcelona, Cadiz, Madrid, Santander, Seville, Valladolid

2024-10-10

Active, closed

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06598943Ulcerative Colitis, Ulcerative Colitis Chronic

DrugMirikizumab

Eli Lilly and Company

Phase 2

143

Barcelona, Ciudad Real, Córdoba, Huelva, Las Palmas de GC, Madrid, Santiago de Compostela, Seville

2024-10-10

Active, closed

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

NCT06630286HIV-1-infection

DrugsISL/LEN·B/F/TAF

Gilead Sciences

Phase 3

609

A Coruña, Barcelona, Málaga

2024-10-09

Active, closed

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

NCT05417789TGCT

DrugEmactuzumab

SynOx Therapeutics Limited

Phase 3

128

Zaragoza, Barcelona, Seville, Valencia

2024-10-09

Recruiting

Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.

NCT06423898Endocarditis, Infective

DrugAmpicillin

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 4

284

Alava, Barakaldo, Barcelona, Donostia / San Sebastian, Granada, Logroño, Madrid, Málaga

2024-10-09

Recruiting

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06470048Diffuse Cutaneous Systemic Sclerosis

DrugIanalumab

Novartis Pharmaceuticals

Phase 2

200

Málaga, Valencia, Barcelona, Madrid, Salamanca

2024-10-09

Active, closed

Evaluation of First Year Implementation of Komtü Programme to Improve Emotional Well-being in School.

NCT06488833Psychological Well-Being, Mental Health Wellness

Universitat Autonoma de Barcelona

Not applicable

270

Barcelona

2024-10-08

Active, closed

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

NCT06630299HIV-1-Infection

DrugsAntiretroviral Combinations·ISL/LEN

Gilead Sciences

Phase 3

600

Barcelona, Madrid, Seville

2024-10-08

Active, closed

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

NCT06335979Systemic Lupus Erythematosus, SLE

DrugPIT565

Novartis Pharmaceuticals

Phase 1

Santiago Compostela, Barcelona, Madrid

2024-10-08

Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386Non-small Cell Lung Cancer

DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin

Bristol-Myers Squibb

Phase 3

1,000

A Coruña, Barcelona, L'Hospitalet de Llobregat, Palma, Madrid, Majadahonda, Valencia, Málaga

2024-10-07

Active, closed

Endoluminal Vacuum Therapy to Prevent Anastomotic Leakage After Esophagectomy Due to Esophageal Cancer

NCT06097078Esophageal Cancer, Esophagus Cancer, Anastomotic Leak

Aesculap AG

Observational

Barcelona

2024-10-07

Recruiting

Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy

NCT06730464Dilated Cardiomyopathy, Arrhythmogenic Cardiomyopathy, Ventricular Arrhythmia, Hypertrophic Cardiomyopathies

Centro Medico Teknon

Observational

500

Barcelona, Seville

2024-10-07

Recruiting

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

NCT06602479Migraine

AbbVie

Phase 2

488

Badajoz, Barcelona, Madrid, Valencia

2024-10-07

Active, closed

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors

NCT06631079Solid Tumor

NEC Bio B.V

Phase 1/2

Barcelona, Madrid, Santiago de Compostela

2024-10-07

Recruiting

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

NCT06598306Extensive Stage Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 1

220

Málaga, Barcelona, Valencia, Madrid

2024-10-07

Recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814Metastatic Non-small Cell Lung Cancer

DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

744

A Coruña, Barakaldo, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga

2024-10-04

Recruiting

Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

NCT06634199Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation

DrugDurvalumab

Fundación GECP

Observational

Ferrol, Alicante, Badalona, Barcelona, Bilbao, Ciudad Real, Girona, A Coruña

2024-10-03

Recruiting

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

NCT05947955Acute Respiratory Distress Syndrome, Infections

BioAegis Therapeutics Inc.

Phase 2

600

Barcelona, Madrid, Tarragona

2024-10-03

Recruiting

A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

NCT06343805Primary Myelofibrosis

Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

Phase 1

256

Barcelona, Madrid

2024-10-03

Active, closed

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

NCT06568237Multiple System Atrophy

DrugEmrusolmin

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

349

Barakaldo, Barcelona, Elche, Madrid, Pamplona, Seville, Valencia

2024-10-02

Recruiting

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

NCT06545955Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

DrugsNadofaragene Firadenovec·Docetaxel·Gemcitabine·Pembrolizumab

Ferring Pharmaceuticals

Phase 3

250

Santander, Barcelona, Córdoba, A Coruña, Alcorcón, Madrid, Pamplona, Bilbao

2024-10-01

Recruiting

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06510374Intermediate Risk Non-Muscle Invasive Bladder Cancer

DrugNadofaragene Firadenovec

Ferring Pharmaceuticals

Phase 3

454

Santander, Barcelona, Córdoba, A Coruña, Granada, Alcorcón, Madrid, Bilbao

2024-10-01

Active, closed

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

NCT06506955Advanced/Metastatic Cancer

DrugFutibatinib

Taiho Oncology, Inc.

Phase 2/3

Barcelona, Madrid

2024-10-01

By invitation

Effectiveness of Online Training in Cardiopulmonary Resuscitation Maneuvers for a Network of Volunteers.

NCT06275984Cardiorespiratory Arrest, Cardiopulmonary Arrest With Successful Resuscitation

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Not applicable

156

Barcelona

2024-10-01

Recruiting

Multicenter Trial of Proximal Femoral Guided Growth in Children With CP and Hips at Risk of Dislocation (GGSH-MC)

NCT06956729Cerebral Palsy

Fundación para la investigación biomética Hospital Infantil Universitario Niño Jesús

Not applicable

A Coruña, Almería, Seville, Palma, Salamanca, Barcelona, Donostia / San Sebastian, Madrid

2024-10-01

Active, closed

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779Severe Asthma

AstraZeneca

Phase 3

310

Badalona(Barcelona), Barcelona, Lugo, Madrid

2024-09-30

Recruiting

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

NCT05663515Pancreatic Cancer

DrugExenatide

AstraZeneca

Observational

24,000

Barcelona

2024-09-30

By invitation

Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma

NCT06609239Asthma

DrugLunsekimig

Sanofi

Phase 2

900

Barcelona, Madrid

2024-09-30

Recruiting

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

NCT06551142Neoplasms

DrugsRis-Rez·Tarlatamab·Dostarlimab·Cetuximab

GlaxoSmithKline

Phase 1

845

Badajoz, Barcelona, Madrid, Málaga, Valencia, Zaragoza

2024-09-30

Recruiting

First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors

NCT06622486Solid Tumor, Adult

Egle Therapeutics

Phase 1/2

Barcelona, Madrid, Pamplona, Valencia

2024-09-27

Recruiting

RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia

NCT06919341ITP - Immune Thrombocytopenia, Primary Immune Thrombocytopenia (ITP)

Fundación Española de Hematología y Hemoterapía

Observational

1,000

A Coruña, Palma, Barcelona, Terrassa, Bilbao, Torrelavega, Castellon, Algeciras

2024-09-27

Recruiting

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

NCT06613698Liver Diseases, Alcoholic

DrugGSK4532990

GlaxoSmithKline

Phase 2

393

Barcelona, León, Madrid, Santander, Seville, Valencia, Valladolid, Vigo

2024-09-27

Active, closed

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

NCT06660394Dravet Syndrome

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga

2024-09-25

Recruiting

A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems

NCT06512454Alpha1-Antitrypsin Deficiency

Takeda

Observational

500

Barcelona

2024-09-25

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220Head and Neck Squamous Cell Carcinoma

DrugsPetosemtamab·Pembrolizumab

Merus B.V.

Phase 3

699

Badalona, Barcelona, Madrid, Marbella, Pamplona, Valencia

2024-09-25

Active, closed

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Adagrasib·Sotorasib

Hoffmann-La Roche

Phase 3

338

L'Hospitalet de Llobregat, Seville, Barcelona, Madrid, Málaga, Valencia, Zaragoza

2024-09-23

Active, closed

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

NCT06553027Parkinson Disease

Cerevance

Phase 3

330

Seville, Sant Cugat del Vallès, Barakaldo, San Sebastián, Valencia, Barcelona, Madrid

2024-09-20

Recruiting

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor

DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin

Eli Lilly and Company

Phase 1

340

Barcelona, Madrid

2024-09-19

Recruiting

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT06635148Geographic Atrophy, Macular Degeneration

Janssen Research & Development, LLC

Phase 2/3

274

Barcelona, Burjassot, Córdoba, Madrid, Majadahonda, Pamplona, Sant Cugat del Vallès, Seville

2024-09-19

Active, closed

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951Melanoma

DrugsFianlimab·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

151

Granada, Málaga, Palma, Badalona, Barcelona, El Palmar, Oviedo, Madrid

2024-09-18

Active, closed

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

NCT06558279Myasthenia Gravis, Ocular

argenx

Phase 3

141

Barcelona, Madrid, San Sebastián, Valencia

2024-09-18

Recruiting

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

NCT06542250B-cell Malignancies

DrugAZD5492

AstraZeneca

Phase 1/2

174

Barcelona, L'Hospitalet de Llobregat, Madrid

2024-09-18

Active, closed

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer

DrugsAnvumetostat·Sotorasib·Pemetrexed·Paclitaxel

Amgen

Phase 1

Barcelona, Madrid

2024-09-17

Active, closed

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

NCT06559163Systemic Lupus Erythematosus

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 2

190

Barcelona, Madrid, Seville

2024-09-17

Active, closed

A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy

NCT06537999Multifocal Motor Neuropathy

DrugClaseprubart

Dianthus Therapeutics

Phase 2

Alicante, Barcelona

2024-09-17

Recruiting

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

NCT06567015Non-small Cell Lung Cancer (NSCLC)

Pierre Fabre Medicament

Phase 1/2

171

Barcelona, Logroño, Madrid

2024-09-17

Active, closed

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

NCT06497504Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

153

Barcelona, Córdoba, Madrid

2024-09-17

Recruiting

European Registry of Next Generation Imaging in Advanced Prostate Cancer

NCT06866782Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)

Fundacio Puigvert

Observational

600

Barcelona, Córdoba, Madrid, San Cristóbal de La Laguna, Santander, Santiago de Compostela

2024-09-17

Active, closed

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

NCT06537310Cancer-Neoplasms

Hoffmann-La Roche

Phase 1

Pamplona, Barcelona, Madrid

2024-09-16

Recruiting

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

NCT06140524Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 2

116

Granada, Terrassa, El Palmar, Gijón, Barcelona, Madrid, Murcia

2024-09-16

Recruiting

STAR-PAK Study: Evaluating the Safety and Efficacy of PAK® (Paclitaxel Coated Balloon) in Treating Atherosclerotic Femoro-Popliteal Lesions

NCT06734221Popliteal Artery Stenosis Above the Knee, Peripheral Artery Disease, Superficial Femoral Artery Stenosis

Balton Sp.zo.o.

Not applicable

120

Barcelona

2024-09-15

Recruiting

Sacituzumab govitEcan in THYroid Cancers

NCT06235216Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer

DrugSacituzumab Govitecan

Grupo Espanol de Tumores Neuroendocrinos

Phase 2

Barcelona, Ferrol, Hospitalet de Llobregat (Barcelona), Madrid, Murcia, Oviedo, Santander, Zaragoza

2024-09-13

Recruiting

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil

Eli Lilly and Company

Phase 1

630

Barcelona, Madrid

2024-09-12

Active, closed

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

DrugsABP 234·Pembrolizumab

Amgen

Phase 3

163

A Coruna Galicia, A Coruña, Alicante, Badalona, Barcelona, Jerez de la Frontera, Madrid, Mataró

2024-09-12

Active, closed

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis

Priovant Therapeutics, Inc.

Phase 3

371

Barcelona, Madrid, Valladolid

2024-09-11

Recruiting

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

NCT06559150Non-cystic Fibrosis Bronchiectasis

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Phase 2

284

A Coruña, Barcelona, Madrid

2024-09-11

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

NCT06572384Lung Diseases, Interstitial

DrugBelimumab

GlaxoSmithKline

Phase 3

440

Pamplona Iruna, Barcelona, Córdoba, Granada, Madrid, Málaga, Santander, Seville

2024-09-11

Recruiting

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

NCT06379789Hemophilia B

Regeneron Pharmaceuticals

Phase 1/2

130

Seville, A Coruña, El Palmar, Oviedo, Barcelona, Madrid, Valencia, Zaragoza

2024-09-11

Active, closed

Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome

NCT06315751Tourette Syndrome

Noema Pharma AG

Phase 2

164

Barcelona, Burgos, Madrid, Oviedo, Sant Cugat del Vallès, Seville

2024-09-10

Active, closed

RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

NCT06243458Low Risk Myelodysplastic Syndromes

DrugRVU120

GCP-Service International West GmbH

Phase 2

Barcelona, León, Madrid, Pamplona, Salamanca, Valencia

2024-09-10

Recruiting

Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter

NCT06370182Acute Ischemic Stroke From Large Vessel Occlusion

Anaconda Biomed S.L.

Not applicable

327

Barcelona, Madrid, Murcia, Oviedo

2024-09-09

Recruiting

Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

NCT06652633Hematological Malignancies

Lakefront Biotherapeutics NV

Phase 3

546

Barcelona

2024-09-09

Active, closed

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT06311721Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

DrugsABP 234·Keytruda·Pembrolizumab

Amgen

Phase 3

315

Alicante, Barcelona, Jaén, Madrid, Mataró, Málaga, Oviedo, Seville

2024-09-09

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

NCT06476808High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb

Phase 1

240

Barcelona, Avda.Pio XII 36,

2024-09-06

Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

NCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

DrugGlofitamab

Arvinas Inc.

Phase 1

329

El Palmar, Pamplona, Barcelona, Madrid, Salamanca

2024-09-05

Active, closed

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

179

Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Salamanca, Valencia

2024-09-04

Recruiting

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

NCT06548542Crohn's Disease

DrugsABBV-8736·Trosunilimab·Lutikizumab·Risankizumab

AbbVie

Phase 2

590

Santiago de Compostela, Seville, Barcelona, Madrid, Pontevedra, Valencia

2024-09-04

Recruiting

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

2,150

Sabadell, Santander, Majadahonda, Barcelona, Madrid, Seville, Valencia

2024-09-04

Active, closed

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

NCT06616974Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction

Tectonic Therapeutic

Phase 2

191

Barcelona, Madrid, Santiago de Compostela, Valencia

2024-09-04

Recruiting

EEAP Using Moses 2.0 Technology vs the Thulium Fiber Laser in Medium-Large Prostates

NCT06565741Prostatic Hyperplasia, Surgery, Endoscopic Anatomical Enucleation of the Prostate (EEAP)

Fundacio Puigvert

Not applicable

120

Barcelona, L'Hospitalet de Llobregat

2024-09-03

Recruiting

ATLAS (AltaValve) Pivotal Trial

NCT06465745Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation

4C Medical Technologies, Inc.

Not applicable

450

Barcelona, Madrid, Vigo

2024-09-03

Active, closed

Duloxetine to Prevent Chronic Postsurgical Pain After Inguinal Hernia Repair in Patients at High Risk

NCT06606067Chronic Post-surgical Pain

DrugDuloxetine

Parc de Salut Mar

Phase 3

294

Barcelona

2024-09-03

Recruiting

First in Human Study to Assess Safety and Efficacy of an Implantable Nitinol Device in the Treatment of Keratoconus

NCT06451718Keratoconus

Recornea Srl

Not applicable

Barcelona

2024-09-03

Recruiting

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

NCT06274801Pulmonary Arterial Hypertension

Gossamer Bio USA, Inc.

Phase 3

330

Barcelona, Madrid, Santander, Seville, Toledo

2024-09-03

Recruiting

Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT06544785Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsZanubrutinib Product·Zanubrutinib·Obinutuzumab

PETHEMA Foundation

Phase 2

106

Alicante, Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Marbella, Málaga, Oviedo

2024-09-02

Recruiting

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

NCT06576271Systemic Lupus Erythematosus

DrugBelimumab

GlaxoSmithKline

Phase 1

142

Barcelona, Bilbao, Pamplona, Sabadell Barcelona, Valladolid

2024-09-02

Active, closed

New Diagnostic Tools in the Evaluation of the Posterior Compartment of the Women Pelvic Floor

NCT06525207Anal Incontinence, Obstructive Defecation

Hospital Clinic of Barcelona

Observational

Barcelona

2024-09-01

Active, closed

POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol After Gastric Surgery (POWER 4 + 3)

NCT06790238Adenocarcinoma of Stomach, Critical Pathways, Enhanced Recovery After Surgery (ERAS) Protocol, Retrospective Studies

Grupo Español de Rehabilitación Multimodal

Observational

350

Alcázar de San Juan, Barakaldo, Barcelona, Bilbao, Ciudad Real, Fuenlabrada, Guadalajara, Inca

2024-09-01

Recruiting

Prospective Observational Study to Evaluate the Safety of Immunotherapy as a Treatment for Hymenoptera Venom Allergy

NCT06782217Allergy, Insect Venom, Allergy Insect Stinging, Insect Sting Allergy

DrugVenox

Inmunotek S.L.

Observational

120

Ferrol, Plasencia, Burela de Cabo, Monforte de Lemos, A Coruña, Barcelona, Lugo, Ourense

2024-09-01

Recruiting

CRS Questionnaire Validation Project

NCT06970977Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

The European Forum for Research and Education in Allergy and Airway Diseases

Observational

1,000

A Coruña, Barcelona, Cadiz, Madrid, Ponferrada, Santander, Seville, Valencia

2024-09-01

Recruiting

AN EXTENDED COHORT STUDY TO INVESTIGATE SUICIDAL BEHAVIOR IN SPAIN (THE SURVIVE 2 STUDY)

NCT07554729Suicidal Behaviors

Parc de Salut Mar

Observational

3,600

Barcelona

2024-09-01

Active, closed

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer

DrugsS095029·Keytruda·Pembrolizumab

Servier Bio-Innovation LLC

Phase 1/2

Barcelona, Madrid, Santander, Valencia

2024-08-31

Recruiting

The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

NCT05973851Major Depressive Disorder, Treatment Resistant Depression

DrugsSecond-line Antidepressants·Ketamine Hydrochloride·Escitalopram·Esketamine

Dr. Inge Winter

Phase 3

418

Barcelona

2024-08-31

Active, closed

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

NCT06503731Antibody-mediated Rejection

argenx

Phase 2

Barcelona, Zaragoza

2024-08-30

Active, closed

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06564142Immunoglobulin A Nephropathy

DrugPovetacicept

Alpine Immune Sciences Inc, A Subsidiary of Vertex

Phase 3

605

Barcelona, Córdoba, Lleida, Madrid, Pamplona, Santiago de Compostela, Seville, Valencia

2024-08-30

Active, closed

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

NCT06331299Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder

UroGen Pharma Ltd.

Phase 3

Málaga, Barcelona, Madrid

2024-08-29

Active, closed

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

NCT06557772Coeliac Disease, Celiac Disease

DrugAmlitelimab

Sanofi

Phase 2

229

Barcelona, Chiclana de la Frontera, Las Palmas de Gran Canaria, Seville, Madrid, Málaga

2024-08-29

Recruiting

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation

DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin

Bayer

Phase 3

555

Badalona, Majadahonda, Pamplona, A Coruña, Barcelona, Madrid, Valencia

2024-08-28

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441Endometrial Cancer

DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin

Gilead Sciences

Phase 3

640

A Coruña, Barcelona, Jaén, Madrid, Málaga, Palma, Sabadell, San Sebastián

2024-08-28

Active, closed

Phase IIa Study Evaluating AZD7798 in Crohn's Disease

NCT06450197Moderate to Severe Crohn's Disease

DrugAZD7798

AstraZeneca

Phase 2

120

Barcelona, Seville

2024-08-28

Active, closed

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754Non-small Cell Lung Cancer

DrugsVolrustomig·Ramucirumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

194

A Coruña, Alcorcón, Barcelona, Madrid, Málaga, Pamplona, Santander, Santiago de Compostela

2024-08-27

Recruiting

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

NCT06500884Multiple Myeloma

DrugsRamantamig·Talquetamab

Janssen Research & Development, LLC

Phase 2

210

Badalona, Barcelona, El Palmar, Jerez de la Frontera, Madrid, Pozuelo de Alarcón, Salamanca

2024-08-26

Active, closed

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

NCT06413498Multiple Myeloma

DrugsAnitocabtagene Autoleucel·Carfilzomib·Pomalidomide·Bortezomib

Kite, A Gilead Company

Phase 3

452

Badalona, Barcelona, El Palmar, Madrid, Pamplona, Salamanca, Santander, Seville

2024-08-23

Active, closed

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer

Alterome Therapeutics, Inc.

Phase 1

110

Barcelona, Madrid

2024-08-22

Recruiting

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy

DrugsRiliprubart·IVIG

Sanofi

Phase 3

160

Santiago de Compostela, Barcelona, Majadahonda, Pamplona, Málaga, Sabadell, Santa Cruz de Tenerife, Valencia

2024-08-21

Active, closed

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

NCT06284954Dermatomyositis, Myositis

DrugEmpasiprubart

argenx

Phase 2

Barcelona, Seville, Valladolid

2024-08-20

Recruiting

CEB-01 in Locally Resectable Pancreatic Cancer

NCT06538857Pancreatic Carcinoma

DrugCEB-01

CEBIOTEX

Early Phase 1

Barcelona, Madrid, Seville, Valencia

2024-08-20

Recruiting

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

NCT06371417Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)

DrugRAY121

Chugai Pharmaceutical

Phase 1

144

Pamplona, Madrid, Barcelona, Córdoba, Seville, Valencia

2024-08-19

Recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma

DrugZilovertamab vedotin

Merck Sharp & Dohme LLC

Phase 1/2

Esplugas de Llobregat, Madrid, Valencia, Barcelona

2024-08-16

Active, closed

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

NCT06247995Breast Cancer

DrugsGa-NeoB·Lu-NeoB·Capecitabine

Novartis Pharmaceuticals

Phase 1/2

L'Hospitalet de Llobregat, Barcelona, Madrid

2024-08-14

Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

NCT06435429Metastatic HER2-positive Breast Cancer

DrugsZanidatamab·Eribulin·Vinorelbine·Trastuzumab

Jazz Pharmaceuticals

Phase 3

550

A Coruña, Badajoz, Barcelona, Elche, Granada, Madrid, San Cristóbal de La Laguna, Seville

2024-08-13

Recruiting

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

NCT06545942Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer

DrugOlaparib

MOMA Therapeutics

Phase 1

220

Barcelona, Madrid

2024-08-13

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Barcelona, Madrid, Málaga, Santander

2024-08-12

Active, closed

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06571045Diabetic Macular Edema (DME)

DrugsRestoret·Lucentis·Ranibizumab

EyeBiotech Ltd.

Phase 2/3

984

Burjassot, Barcelona, Santiago de Compostela, Seville, Zaragoza

2024-08-07

Recruiting

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

NCT06549595Untreated Follicular Lymphoma

DrugsSurovatamig·R-Chop

AstraZeneca

Phase 3

1,018

Barcelona, El Palmar, Girona, Las Palmas de Gran Canaria, Madrid, Oviedo, Pamplona, Santander

2024-08-07

Active, closed

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

NCT06421935Advanced Solid Tumor

DrugsHRS-1167·Tuvusertib·Prednisone/Prednisolone·Abiraterone

EMD Serono Research & Development Institute, Inc.

Phase 1

Barcelona, Madrid, Pozuelo de Alarcón

2024-08-07

Recruiting

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

NCT06292780Relapsed/Refractory Systemic Light Chain Amyloidosis

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 1/2

220

Palma, Pamplona, Gijón, Barcelona, Valencia

2024-08-07

Active, closed

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT06162572Non-small Cell Lung Cancer (NSCLC)

DrugsS095029·Cemiplimab

Servier Bio-Innovation LLC

Phase 1/2

102

Barcelona, Madrid, Málaga, Valencia

2024-08-07

Recruiting

A Low-Cost Balance Training Platform Using Augmented Reality in Neurorehabilitation: a Usability Study

NCT06627387Postural Balance, Cerebrovascular Disorders, Neurodegenerative Diseases, Augmented Reality

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

Barcelona

2024-08-06

Active, closed

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

NCT06492291Hypercholesterolemia

DrugsEnlicitide·Enlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 3

3,000

Málaga, Centelles, Barcelona, Figueres, A Coruña, Santiago de Compostela, Pozuelo de Alarcón, Alcorcón

2024-08-05

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

A Coruña, Barcelona, Cáceres, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2024-08-01

Active, closed

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

NCT06534892Respiratory Syncytial Virus Infections

DrugRSVPreF3 OA vaccine

GlaxoSmithKline

Phase 3

10,212

Santiago de Compostela, Centelles, Vic, Majadahonda, Alcorcón, Barcelona, Madrid, Valencia

2024-08-01

Recruiting

The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

NCT05958875Schizophrenia and Related Disorders, Early Treatment-Resistance

DrugsSecond-line Antipsychotics·Clozapine

Dr. Inge Winter

Phase 4

418

Barcelona

2024-08-01

Active, closed

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

NCT06440967Hot Flashes

DrugsFezolinetant·Tamoxifen

Astellas Pharma Global Development, Inc.

Phase 3

982

Barcelona, Elche, Girona, Granada, Jaén, León, Madrid, Majadahonda

2024-07-31

Active, closed

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

NCT06517758Generalized Myasthenia Gravis

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

146

Santiago Compostela, L'Hospitalet de Llobregat, Alicante, Barcelona, Lleida, Madrid, Málaga, Valencia

2024-07-31

Recruiting

HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life

NCT05373264ADPKD

DrugHydrochlorothiazide

University Medical Center Groningen

Phase 3

300

Alcázar de San Juan, Barcelona, Madrid

2024-07-31

By invitation

A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients

NCT06445673Pulmonary Arterial Hypertension

AOP Orphan Pharmaceuticals AG

Observational

110

Barcelona, Madrid

2024-07-31

Recruiting

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

NCT06216301Metastatic Non-small Cell Lung Cancer

DrugPembrolizumab

NovoCure GmbH

Phase 3

734

Elche, Seville, Barcelona, Torrejón de Ardoz, Lleida, Madrid, Málaga, Pamplona

2024-07-31

By invitation

Long-term Safety and Tolerability of BHV-7000

NCT06443463Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2

660

Badalona, L'Hospitalet de Llobregat, Pamplona, Vigo, Barcelona, Granada, Madrid, Málaga

2024-07-30

Active, closed

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

NCT06510816Geographic Atrophy

DrugVonaprument

Annexon, Inc.

Phase 3

659

Valencia, Barcelona, Córdoba, Madrid, Majadahonda, Sant Cugat del Vallès, Santiago de Compostela, Seville

2024-07-30

Active, closed

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

NCT06365853Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive

DrugsMIRV·Mirvetuximab Soravtansine

AbbVie

Phase 2

108

Barcelona, Cáceres, Jaén, Madrid, Valencia

2024-07-29

Recruiting

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

NCT06559306Depressive Disorder, Major

DrugSeltorexant

Janssen Research & Development, LLC

Phase 3

752

Barcelona, Bilbao, Collado Villalba, Madrid, Torrevieja

2024-07-25

Active, closed

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180Cervical Cancer

DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

686

Barcelona, L'Hospitalet de Llobregat, Girona, Madrid, Valencia, Córdoba

2024-07-24

Active, closed

Post Market Clinical Follow up Evaluating the Performance and Safety of Juläine(TM) on Nasolabial Fold Wrinkles

NCT06471933Nasolabial Fold

Nordberg Medical AB

Not applicable

Barcelona

2024-07-24

Active, closed

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

NCT06355531Progressive Supranuclear Palsy

Ferrer Internacional S.A.

Phase 2

241

A Coruña, Badalona, Barakaldo, Barcelona, Madrid, Pamplona, Seville, Valencia

2024-07-23

Active, closed

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

NCT06172127HER2-positive Breast Cancer

DrugsPhesgo·Trastuzumab deruxtecan

MedSIR

Phase 2

165

Seville, Alicante, Barcelona, Bilbao, Castellon, Córdoba, Granada, León

2024-07-22

Recruiting

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

NCT06362252Extensive Stage-small Cell Lung Cancer

DrugsIfinatamab Deruxtecan·Atezolizumab·Carboplatin

Daiichi Sankyo

Phase 1/2

123

Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Vigo

2024-07-22

Active, closed

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

NCT06384261Leukemia, Myeloid, Acute

DrugsCusatuzumab·Azacitidine·Venetoclax

OncoVerity, Inc.

Phase 2

140

Barcelona, Pamplona, Salamanca

2024-07-22

Active, closed

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

NCT06544616Alzheimer Disease

Janssen Pharmaceutica N.V., Belgium

Phase 2

Barcelona, Getxo, Lleida, Madrid, Pamplona, Pozuelo de Alarcón, Sant Cugat del Vallès, Terrassa

2024-07-22

Recruiting

Oral Anticoagulation Versus Left Atrial Appendage Occlusion Added to Direct Oral Anticoagulation in Patients with Stroke Despite Oral

NCT06869811Left Atrial Appendage Closure

Hospital Clinic of Barcelona

Not applicable

380

Barcelona

2024-07-22

Recruiting

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

NCT06979323Asthma

DrugDepemokimab

GlaxoSmithKline

Phase 3

150

Barcelona, Benalmádena, Madrid, Palma de Mallorca, Santander

2024-07-19

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575Biliary Tract Cancer

DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin

Jazz Pharmaceuticals

Phase 3

286

Santiago de Compostela, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia

2024-07-19

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

NCT06455202Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

976

Barcelona, Cadiz, Madrid, Pamplona, Pozuelo de Alarcón, Seville, Torrejón de Ardoz, Valencia

2024-07-19

Recruiting

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

NCT06456580Generalized Myasthenia Gravis

DrugTelitacicept

Vor Biopharma

Phase 3

180

Alicante, Barcelona, Terrassa, Bilbao, Valencia

2024-07-17

Recruiting

The Influence of the Vaginal Microbiome on Clinical Pregnancy in Patients Undergoing a Euploid Embryo Transfer

NCT06643065Vaginal Microbiome

Fundación IVI

Observational

1,573

Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia, Vigo, Zaragoza

2024-07-17

Active, closed

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

NCT06483334Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma

DrugsEnfortumab Vedotin·Sacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

Barcelona, Madrid

2024-07-17

Recruiting

Feasibility of ONCOhabitats for Surgical and Treatment Planning in IDH-Wildtype Glioblastoma (SINUE)

NCT07111195Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Juan M Garcia-Gomez

Observational

140

Alicante, Barcelona, Murcia, Santa Cruz de Tenerife, Valencia

2024-07-16

Active, closed

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

NCT06161441Resectable Non-small Cell Lung Cancer

DrugsFianlimab·Cemiplimab·Paraplatin·Taxol

Regeneron Pharmaceuticals

Phase 2

195

Santiago de Compostela, Elche, Granada, Palma, Barcelona, Majadahonda, El Palmar, Pamplona

2024-07-16

Recruiting

TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic Ataxias

NCT07798674Hereditary Spastic Paraplegia, Spastic Ataxia

Heidelberg University

Observational

4,000

Barcelona, Santander

2024-07-16

Active, closed

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346Essential Thrombocythemia

DrugsBomedemstat·Hydroxyurea

Merck Sharp & Dohme LLC

Phase 3

300

Badalona, L'Hospitalet de Llobregat, Santander, Barcelona, Madrid, Marbella, Salamanca

2024-07-16

Recruiting

Tapping Test and the Archimedean Spiral for the Differential Diagnosis of Tremor. Machine Learning Approach

NCT06378619Tremor, Essential Tremor, Parkinson Disease

Consorci Sanitari de l'Alt Penedès i Garraf

Observational

110

Barcelona

2024-07-15

Active, closed

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic

DrugRiliprubart

Sanofi

Phase 3

109

Santiago de Compostela, Barcelona, Bilbao, Majadahonda, Pamplona, Oviedo, Sabadell, Santa Cruz de Tenerife

2024-07-12

Recruiting

Left Septal or Deep Septal Pacing to Prevent Pacing-induced Cardiomyopathy

NCT06474819Complete Heart Block, Second Degree Atrioventricular Block Möbitz Type II

Institut d'Investigació Biomèdica de Bellvitge

Not applicable

326

Barcelona, Castellon, Granada, L'Hospitalet de Llobregat, Valencia, Zaragoza

2024-07-12

Recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

NCT06264180Advanced Melanoma

DrugsVusolimogene Oderparepvec·Relatlimab·Opdivo·Nivolumab

Replimune, Inc.

Phase 3

400

Barcelona, El Palmar, Madrid, Pamplona

2024-07-11

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT06445023Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

963

Sabadell, Alicante, Barcelona, Córdoba, Madrid, Salamanca, Villarreal de Huerva

2024-07-11

Recruiting

Fibrosis Lessens After Metabolic Surgery

NCT06374875Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis

The Cleveland Clinic

Phase 4

120

Barcelona

2024-07-11

Active, closed

Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II

NCT06392009Tuberous Sclerosis Complex, Focal Cortical Dysplasia

DrugRadiprodil

GRIN Therapeutics, Inc.

Phase 1/2

Barcelona, Madrid

2024-07-10

Recruiting

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

DrugIvosidenib

Servier Bio-Innovation LLC

Phase 3

136

Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia

2024-07-09

Recruiting

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

NCT06024746Heart Failure

DrugsFinerenone·Dapagliflozin

Colorado Prevention Center

Phase 3

1,500

A Coruña, Santiago de Compostela, Madrid, Málaga, Manises, Valencia, Barcelona

2024-07-09

Recruiting

Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer

NCT06582628Metastatic Prostate Cancer

DrugEnzalutamide

Fundacion Oncosur

Phase 2

Badalona, Barcelona, Sabadell, Santander, Cadiz, Madrid, Málaga, Barakaldo

2024-07-05

Active, closed

A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

NCT06526182Dermatitis, Atopic, Eczema

DrugLebrikizumab

Almirall, S.A.

Phase 3

520

Alicante, Barcelona, Granada, Valencia

2024-07-03

Recruiting

A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

NCT06431594Solid Tumors, Neoplasms

DrugMocertatug rezetecan

GlaxoSmithKline

Phase 1

675

Barcelona, Córdoba, Girona, Madrid, Pozuelo de AlarcOn Madr

2024-07-02

Recruiting

Improving the Treatment of Anorexia Nervosa in Children Through Virtual Reality Body Exposure

NCT06166355Anorexia Nervosa

University of Barcelona

Not applicable

108

Barcelona

2024-07-01

Recruiting

A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).

NCT05895136Liver Cirrhosis, Decompensated Cirrhosis of Liver, Acute on Chronic Liver Failure (ACLF)

DrugsHuman albumin·Enoxaparin

European Foundation for Study of Chronic Liver Failure

Phase 2

Barcelona, Madrid

2024-07-01

Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm

Eli Lilly and Company

Phase 1

420

Barcelona, Madrid, Seville

2024-07-01

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737Cutaneous Lupus Erythematosus

AstraZeneca

Phase 3

339

Barcelona, Castellon, Granada, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Salamanca

2024-06-29

Recruiting

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

NCT06263231Sarcoma,Soft Tissue

DrugsINT230-6·Trabectedin·Pazopanib·Eribulin

Intensity Therapeutics, Inc.

Phase 3

333

Barcelona, Madrid

2024-06-28

Recruiting

Assessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis

NCT06873308Schistosomiasis

IRCCS Sacro Cuore Don Calabria di Negrar

Not applicable

278

Almería, Barcelona

2024-06-28

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZongertinib·Zanidatamab·Trastuzumab emtansine·MFOLFOX6

Boehringer Ingelheim

Phase 1/2

768

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Seville, Valencia

2024-06-28

Recruiting

Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 OUS Study)

NCT06495970Pulmonary Hypertension

Gradient Denervation Technologies

Not applicable

Badalona, Barcelona, Valencia

2024-06-26

Recruiting

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

NCT06463587Generalized Myasthenia Gravis

DrugCladribine

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 3

264

Badalona, Córdoba, Oviedo, Barcelona, Valencia

2024-06-25

Active, closed

Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

NCT06359002Relapsed / Refractory AML, Relapsed / Refractory MDS

Byondis B.V.

Phase 1

Badalona, Barcelona, Cáceres, Salamanca, Valencia

2024-06-25

Recruiting

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR

AstraZeneca

Observational

1,850

Huelva, Bilbao, Las Palmas de Gran Canaria, Salamanca, Barcelona, Cataluna, Majadahonda, Islas Baleares

2024-06-25

Active, closed

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

10,000

Badalona, Málaga, El Palmar, A Coruña, Alicante, Barcelona, Lleida, Madrid

2024-06-25

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

NCT06496178Head and Neck Squamous Cell Carcinoma

DrugPetosemtamab

Merus B.V.

Phase 3

621

Barcelona, Madrid, Pamplona, Valencia

2024-06-25

Recruiting

Development of a Non-invasive IVD for Endometrial Cancer Screening on High-risk Populations

NCT07148154Endometrial Cancer

MiMARK Diagnostics, S.L.

Observational

3,000

L'Hospitalet de Llobregat, Barcelona

2024-06-24

Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Triple-Negative Breast Cancer

DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine

Merck Sharp & Dohme LLC

Phase 3

1,530

Seville, L'Hospitalet de Llobregat, A Coruña, Madrid, Majadahonda, Valencia, Barcelona

2024-06-24

Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449Polymyositis, Dermatomyositis

AstraZeneca

Phase 3

240

A Coruña, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Sabadell, Valladolid

2024-06-20

Recruiting

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer

DrugsSacituzumab tirumotecan·Fluorouracil·Leucovorin·Adrucil

Merck Sharp & Dohme LLC

Phase 1/2

220

Madrid, Oviedo, Barcelona

2024-06-20

Recruiting

A Trial of Lu AG13909 in Adult Participants With Cushing's Disease

NCT06471829Cushing's Disease

DrugLu AG13909

H. Lundbeck A/S

Phase 2

Barcelona, Madrid

2024-06-19

By invitation

Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1

NCT06131983Muscular Dystrophy, Facioscapulohumeral

Sarepta Therapeutics, Inc.

Phase 1/2

Barcelona, Madrid, Valencia

2024-06-19

Active, closed

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

NCT06388733Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor

DrugsTemodar·Niraparib·Temozolomide

Ivy Brain Tumor Center

Phase 3

450

Barcelona, Córdoba, Girona, Madrid, Pamplona, Salamanca, Seville

2024-06-19

Recruiting

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

6,712

Badalona, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Málaga, Sanlúcar de Barrameda, Santiago de Compostela

2024-06-17

Recruiting

A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

NCT06504147Peritoneal Carcinomatosis, Ovarian Cancer

Oncoinvent Solutions AS

Phase 2

114

Barcelona, Madrid, Pamplona, Valencia

2024-06-15

Active, closed

Extended Validation of Donor-derived Cell-free DNA in Kidney Transplant Recipients

NCT07805343Rejection Acute Renal, Rejection Chronic Renal, Transplantation, Kidney Rejection Transplant

Paris Translational Research Center for Organ Transplantation

Observational

5,000

Barcelona

2024-06-15

Recruiting

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

NCT06122584Prostate Cancer

Drug18F-PSMA-1007

ABX advanced biochemical compounds GmbH

Phase 3

380

Barcelona, Valencia

2024-06-13

Recruiting

The Adjunctive Effect of a Titanium Brush in the Non-Surgical Treatment of Peri-Implantitis

NCT06843928Peri-implantitis, Titanium Brush, Non-surgical Submucosal Debridement

Universitat Internacional de Catalunya

Not applicable

Barcelona

2024-06-12

Active, closed

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

NCT06472076Lung Cancer, Non-Small Cell

DrugsBelrestotug·Dostarlimab·Pembrolizumab

GlaxoSmithKline

Phase 3

A Coruña, Aravaca, BaracaldoVizcaya, Barcelona, Jaén, Las Palmas de Gran Canar, Madrid, Oviedo

2024-06-10

Recruiting

Frailty in Outpatient Digestive Endoscopy

NCT06507527Frailty, Comorbidities and Coexisting Conditions, Complication

Parc de Salut Mar

Observational

1,474

Barcelona

2024-06-10

Recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143Non-small Cell Lung Cancer, NSCLC

DrugsSacituzumab tirumotecan·Nab-paclitaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

851

Santiago de Compostela, Las Palmas de Gran Canaria, Málaga, Barcelona, Madrid, Seville

2024-06-10

Active, closed

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06082167Head and Neck Squamous Cell Carcinoma

DrugsZanzalintinib·Keytruda·Pembrolizumab

Exelixis

Phase 2/3

600

A Coruña, Barcelona, Girona, Madrid, Pamplona, Seville, Valencia, Zaragoza

2024-06-07

Active, closed

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991Multiple Myeloma

DrugTeclistamab

Janssen Research & Development, LLC

Phase 1

108

Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander

2024-06-07

Active, closed

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

NCT06284122Follicular Lymphoma

DrugsBendamustin·Mosunetuzumab·Vincrystine·Obinutuzumab

The Lymphoma Academic Research Organisation

Phase 3

790

Albacete, Barcelona, Las Palmas de Gran Canaria, Lleida, Madrid, Marbella, Oviedo, Salamanca

2024-06-07

Active, closed

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

NCT06411249Systemic Lupus Erythematosus

DrugBelimumab

GlaxoSmithKline

Phase 4

303

Barcelona, Castellon, Córdoba, Murcia, Valladolid, VigoPontevedra, Villajoyosa

2024-06-06

Recruiting

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297Neutropenia

X4 Pharmaceuticals

Phase 3

176

Barcelona, Cáceres, Córdoba, Las Palmas de Gran Canaria, Madrid, Santander, Seville, Valencia

2024-06-06

Active, closed

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

DrugsTarlatamab·Durvalumab

Amgen

Phase 3

563

Málaga, Seville, Barcelona, L'Hospitalet de Llobregat, Pamplona, Valencia, Madrid

2024-06-05

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

NCT06112314Advanced Melanoma

DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab

Immunocore Ltd

Phase 3

680

Santander, El Palmar, A Coruña, Barcelona, Córdoba, Granada, Las Palmas de Gran Canaria, Madrid

2024-06-05

Active, closed

T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases

NCT06048718Breast Cancer, Metastatic Breast Cancer

DrugTrastuzumab deruxtecan

MedSIR

Phase 2

Alicante, Barcelona, Bilbao, Córdoba, Granada, Madrid, Seville, Valencia

2024-06-05

Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801Crohn's Disease

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,200

Badalona, Barcelona, A Coruña, Majadahonda, Torrejón de Ardoz, Madrid, Pontevedra, Santa Cruz de Tenerife

2024-06-05

Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis

DrugsNavtemadlin·Jakavi·Ruxolitinib

Kartos Therapeutics, Inc.

Phase 3

600

Badalona, Barcelona, Cáceres, Las Palmas de Gran Canaria, Madrid, Málaga, Salamanca, Valencia

2024-06-03

Active, closed

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

NCT06507306Solid Tumor, Adult

DrugsKQB198·Tagrisso·Amivantamab·Osimertinib

Kumquat Biosciences Inc.

Phase 1

Barcelona, Madrid, Málaga, Pamplona

2024-06-03

Recruiting

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

NCT06439277Obesity, Weight Gain

DrugTirzepatide

Eli Lilly and Company

Phase 3

300

Barcelona, Córdoba, Madrid, Málaga, Valencia

2024-06-03

Not yet open

Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler

NCT05284474Fetal Growth Retardation, Preeclampsia, Placenta Diseases

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

340

A Coruña, Alicante, Badalona, Barcelona, Cadiz, Elche, Getafe, Gijón

2024-06-03

Active, closed

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

NCT05963074Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma

DrugsVenclyxto·Ibrutinib·Venclexta·Venetoclax

Janssen Research & Development, LLC

Phase 2

333

Barcelona, Córdoba, Madrid, Santander, Santiago de Compostela

2024-05-30

Active, closed

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

NCT06373731Age Related Macular Degeneration (ARMD)

DrugElamipretide

Stealth BioTherapeutics Inc.

Phase 3

313

Barcelona, Valencia

2024-05-30

Active, closed

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

NCT06328738HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification

DrugsELVN-002·Eribulin·Leucovorin·Trastuzumab

Enliven Therapeutics

Phase 1

275

Barcelona, Madrid, Pamplona, Valencia

2024-05-30

Active, closed

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

DrugsAnvumetostat·Modified FOLFIRINOX·Cetuximab·Nab-paclitaxel

Amgen

Phase 1

120

Seville, Barcelona, Madrid

2024-05-29

Active, closed

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

NCT06412666Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy

DrugAficamten

Cytokinetics

Phase 2/3

A Coruña, Barcelona

2024-05-29

Recruiting

Changes in the Dietary Patterns of Adults in Care of a Newly Diagnosed Type 1 Diabetes Mellitus Child

NCT07142681Dietary Habits, Parents, Diabetes Mellitus, Type 1

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Observational

Barcelona

2024-05-29

Recruiting

Shock Wave Therapy for Lower Limb Lymphedema

NCT06454734Lymphedema, Lower Limb

Parc de Salut Mar

Not applicable

Barcelona

2024-05-28

Recruiting

A Study of Pitolisant in Patients With Prader-Willi Syndrome

NCT06366464Prader-Willi Syndrome

DrugPitolisant

Harmony Biosciences Management, Inc.

Phase 3

134

Barcelona, Madrid, Málaga

2024-05-28

Active, closed

Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)

NCT06422936Basal Cell Carcinoma

Highlight Therapeutics

Phase 2

Barcelona, Bilbao, Madrid, Salamanca, Valencia

2024-05-27

Recruiting

Effects of Proprioceptive Sensitivity Stimulation Via the SURA Electrodevice on Kinematics, Kinetics and Spatiotemporal Parameters of Gait.

NCT06395272Stroke

Facultat de ciencies de la Salut Universitat Ramon Llull

Not applicable

Barcelona

2024-05-24

Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

DrugPegozafermin

89bio, Inc.

Phase 3

762

Almería, Badalona, Barcelona, Córdoba, Madrid, Málaga, Pontevedra, Santander

2024-05-24

Recruiting

Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)

NCT06347315Mild Cognitive Impairment

Société des Produits Nestlé (SPN)

Not applicable

380

Alicante, Barcelona, Madrid, Salamanca, Sant Cugat del Vallès, Seville, Valencia

2024-05-24

Recruiting

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

NCT06402201Select Advanced Solid Tumors

CDR-Life AG

Phase 1

Barcelona, Madrid, Valencia

2024-05-24

Recruiting

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

NCT06345729Non-small Cell Lung Cancer

DrugsCalderasib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

348

Las Palmas de Gran Canaria, Leganés, Madrid, Málaga, Barcelona, Seville

2024-05-24

Recruiting

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NCT06343402Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C

DrugsBBO-10203·Pembrolizumab

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Phase 1

350

Horta-Guinardó, Barcelona, Madrid

2024-05-22

Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210Small Cell Lung Cancer

DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan

Daiichi Sankyo

Phase 3

540

Barcelona, Córdoba, Jaén, Jerez de la Frontera, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga

2024-05-21

Recruiting

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

NCT06133972Systemic Lupus Erythematosus

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

550

Santiago Compostela, Badalona, Santander, Barcelona, San Sebastian Reyes, Madrid, Valencia

2024-05-21

Active, closed

Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

NCT05735834Splenic Marginal Zone Lymphoma

DrugsTruxima·Zanubrutinib·Rituximab

International Extranodal Lymphoma Study Group (IELSG)

Phase 3

122

Barcelona, Bilbao, El Palmar, Madrid, Pamplona, Salamanca, San Sebastián, Valencia

2024-05-21

Active, closed

A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

NCT06226571Acute Myeloid Leukemias

DrugRevumenib

Syndax Pharmaceuticals

Phase 1

Santander, Barcelona, Cáceres, Granada, Madrid, Salamanca, Seville, Valencia

2024-05-21

Recruiting

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection

Vedanta Biosciences, Inc.

Phase 3

852

Badalona, Barcelona, Terrassa, San Sebastián, Madrid, Majadahonda, Seville, A Coruña

2024-05-20

Active, closed

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms

DrugsTucatinib·Disitamab Vedotin

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

Barcelona, Bilbao, Erandio Bizkaia, Madrid, Valencia

2024-05-20

Recruiting

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

NCT06353386Prostatic Neoplasms, Castration-Resistant

DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Taxotere

Merck Sharp & Dohme LLC

Phase 1/2

220

L'Hospitalet de Llobregat, Madrid, Barcelona

2024-05-20

Recruiting

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung

DrugsSofe-M·Itraconazole·Bevacizumab·Carboplatin

Eli Lilly and Company

Phase 1

575

Barcelona, Madrid, Valencia

2024-05-20

Recruiting

Combination Therapy for BRAF-V600E Metastatic CRCm

NCT06411600Metastatic Colorectal Cancer

DrugsEncorafenib·Cetuximab·Bevacizumab

Vall d'Hebron Institute of Oncology

Phase 2

Barcelona

2024-05-17

Recruiting

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

NCT06414954Myasthenia Gravis, Myasthenia Gravis, MuSK

NMD Pharma A/S

Phase 2

Barcelona

2024-05-16

Recruiting

Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.

NCT07717268Prostatic Neoplasms, Castration-Resistant

DrugsZytiga·Xtandi

Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

Phase 2

Zaragoza, Barcelona, L'Hospitalet de Llobregat, Bilbao, Salamanca, Valladolid, Terrassa, Santiago de Compostela

2024-05-16

Active, closed

The OPBC-07/microNAC Study

NCT06529302Breast Cancer

University Hospital, Basel, Switzerland

Observational

2,000

Barcelona, Madrid

2024-05-15

Recruiting

CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL

NCT06926205Richter Syndrome

DrugMosunetuzumab

GELLC (Grupo Español de Leucemia Linfocítica Crónica)

Phase 2

Barcelona, L'Hospitalet de Llobregat, Santander, Las Palmas de Gran Canaria, Madrid, Murcia, Marbella, Oviedo

2024-05-15

Active, closed

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)

DrugsKeytruda·Pembrolizumab

Inhibrx Biosciences, Inc

Phase 2/3

410

Santiago, Barcelona, Pamplona, Madrid, A Coruña, Valencia

2024-05-14

Active, closed

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06309966Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2/3

390

Badalona, L'Hospitalet de Llobregat, Pamplona, Vigo, Barcelona, Granada, Madrid, Málaga

2024-05-13

Recruiting

3D Printing Models in Surgical Planning of Osteotomies in Kienbock´s Disease Stages II-III

NCT06460922Kienbock Disease

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Observational

Barcelona

2024-05-10

Recruiting

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

NCT06218875AAA - Abdominal Aortic Aneurysm

W.L.Gore & Associates

Observational

2,000

Barcelona, Seville

2024-05-07

Active, closed

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

DrugNerandomilast

Boehringer Ingelheim

Phase 3

1,666

Alicante, Barcelona, Bilbao, El Palmar, Galdakao, Granada, L'Hospitalet de Llobregat, Madrid

2024-05-06

Active, closed

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311Gastroesophageal Cancer

DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

450

Santander, A Coruña, Pamplona, Oviedo, Barcelona, Madrid

2024-05-03

Active, closed

A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

NCT06402838Alzheimer's Disease

Hoffmann-La Roche

Phase 2

256

Sant Cugat del Vallès, Donostia / San Sebastian, Pozuelo de Alarcón, Salamaca, Barcelona, Córdoba, Madrid, Seville

2024-05-02

Recruiting

A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer

NCT06163391Advanced Solid Tumor, Metastatic Solid Tumor

SOTIO Biotech AG

Phase 1

Barcelona

2024-05-01

Recruiting

Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy

NCT05976685Ischemic Stroke, Atrial Fibrillation

DrugDOAC

Insel Gruppe AG, University Hospital Bern

Not applicable

482

Alicante, Barcelona, Madrid

2024-05-01

Recruiting

Hyperangulated vs Macintosh Blades for Intubation With Videolaryngoscopy in ICU

NCT06322719Acute Respiratory Failure, Intubation, Intubation; Difficult or Failed, Videolaryngoscopy

Hospital Clinico Universitario de Santiago

Not applicable

1,036

Santiago de Compostela, A Coruña, Albacete, Barcelona, Cáceres, Denia, Elche, Gijón

2024-05-01

By invitation

A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)

NCT06431893Homocystinuria

DrugPegtibatinase

Travere Therapeutics, Inc.

Phase 3

100

Barcelona, Madrid, Santiago de Compostela, Seville

2024-04-30

Active, closed

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

DrugRetatrutide

Eli Lilly and Company

Phase 3

10,000

A Coruña, Almería, Alzira, Barcelona, Ferrol, Málaga, Oviedo, Palma de Mallorca

2024-04-30

Active, closed

A Study Evaluating APG777 in Atopic Dermatitis

NCT06395948Atopic Dermatitis

DrugAPG777

Apogee Therapeutics, Inc.

Phase 2

470

Santiago de Compostela, Badalona, Las Palmas de Gran Canaria, Alicante, Barcelona, Madrid, Zaragoza

2024-04-29

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097Non-small Cell Lung Cancer

DrugsDato-DXd·Osimertinib

AstraZeneca

Phase 3

582

A Coruña, Barcelona, Granada, Madrid, Majadahonda, Valencia

2024-04-29

Active, closed

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

NCT06346067Advanced or Metastatic NRAS-mutant Melanoma

DrugsNaporafenib·Temodar·Dacarbazine·Trametinib

Erasca, Inc.

Phase 3

Barcelona, Madrid, Oviedo

2024-04-29

Recruiting

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

DrugLebrikizumab

Eli Lilly and Company

Phase 3

510

Andalucia, Barcelona, Cadiz, Galícia, Madrid, Pamplona

2024-04-29

Recruiting

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961End Stage Kidney Disease

DrugClazakizumab

CSL Behring

Phase 2/3

3,110

Alcobendas, Barcelona, Córdoba, Girona, Granada, Guadalajara, Lleida, Madrid

2024-04-27

Recruiting

Reduction of the Incidence of NAV in Neonatal Units (INBERNAV-Neo)

NCT07240038Pneumonia Ventilator Associated, Pneumonia Neonatal, Healthcare-associated Infections

Biobizkaia Health Research Institute

Observational

1,500

A Coruña, Santiago de Compostela, Albacete, Badalona, Barcelona, Barakaldo, Bilbao, Burgos

2024-04-26

Recruiting

Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)

NCT06599918Fatty Liver, Obesity, Hepatic Fibrosis, NAFLD

DrugNicotinamide

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Phase 2

Barcelona

2024-04-23

Active, closed

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

NCT05972551Osteogenesis Imperfecta

DrugRomosozumab

Amgen

Phase 3

111

Barakaldo, Barcelona, Esplugues de Llobregat, Getafe, Valencia, Madrid

2024-04-22

Recruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

NCT06385080Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Paraplatin·Taxol·Keytruda

Janssen Research & Development, LLC

Phase 1/2

287

Barcelona, Madrid

2024-04-22

Active, closed

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

NCT06194448Lung Cancer

DrugsTagrisso·Osimertinib·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

Barcelona, Donostia / San Sebastian, Granada, Madrid

2024-04-21

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

NCT06319820Non-Muscle Invasive Bladder Neoplasms

DrugGemcitabine

Janssen Research & Development, LLC

Phase 3

641

A Coruña, Alzira, Barcelona, Cadiz, Castellon, Jerez de la Frontera, Madrid, Málaga

2024-04-18

Recruiting

Treatment of Fecal Incontinence and Functional Evacuation Disorders Using Non-instrumental Biofeedback

NCT06273046Fecal Incontinence, Outlet Dysfunction Constipation

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

Barcelona

2024-04-17

Active, closed

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT06253221Cardiomyopathy, Hypertrophic

DrugMavacamten

Bristol-Myers Squibb

Phase 3

Barcelona, Madrid

2024-04-17

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis

DrugEfgartigimod

argenx

Phase 3

119

Alicante, Barcelona, Lleida, Madrid, Santiago de Compostela, Valencia

2024-04-16

Active, closed

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis

DrugTeriflunomide

Sanofi

Phase 3

2,500

A Coruña, Seville, Barcelona, L'Hospitalet de Llobregat, Barakaldo, Santiago de Compostela, Donostia / San Sebastian, Salt

2024-04-16

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

1,200

Pozuelo de Alarcón, Madrid, Valencia, Barcelona, Córdoba, Seville

2024-04-14

Active, closed

A Study of Barzolvolimab in Patients With Prurigo Nodularis

NCT06366750Prurigo Nodularis

DrugBarzolvolimab

Celldex Therapeutics

Phase 2

140

A Coruña, Alicante, Barcelona, Madrid, Seville

2024-04-12

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

NCT06307652Heart Failure and Impaired Kidney Function

AstraZeneca

Phase 3

3,850

A Coruña, Barcelona, Lugo, Madrid, Majadahonda, Seville, Valencia

2024-04-12

Recruiting

A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer

NCT06663839Colorectal Cancer Metastatic

Light Chain Bioscience - Novimmune SA

Phase 1

Barcelona, Madrid

2024-04-12

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

NCT06357533Non-Small Cell Lung Cancer

DrugsRilvegostomig·Dato-DXd·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

675

Alicante, Barcelona, Jerez de la Frontera, Reus, Salamanca

2024-04-11

Recruiting

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

NCT05700149Nodal Marginal Zone Lymphoma

International Extranodal Lymphoma Study Group (IELSG)

Observational

300

Barcelona, L'Hospitalet de Llobregat

2024-04-11

Active, closed

Effects of the Postbiotic Blend ABB C3 on Adiposity and Glucose Metabolism in Children and Adolescents

NCT06309121Obesity, Childhood, Obesity, Adolescent

Fundació Sant Joan de Déu

Not applicable

Barcelona

2024-04-10

Recruiting

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

NCT06311578Neoplasms

DrugCetrelimab

Johnson & Johnson Enterprise Innovation Inc.

Phase 1

126

Barcelona, Madrid

2024-04-10

Recruiting

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064Recurrent or Metastatic Solid Tumors

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 1/2

680

Barcelona, Madrid, Seville

2024-04-10

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/barcelona?page=3

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,238 of those studies with a site in Barcelona.

How many clinical trials are recruiting in Barcelona?

1,669 of the 3,238 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 132 have not yet opened recruitment, 1,365 are active but closed to new participants, and 72 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.